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Abstract 
Abstract 
 
Measurement of drug dissolution and permeation of solid oral dosage 
forms in a combined experiment is a quite obvious research approach that 
nevertheless has only been sparsely considered up to now. In the present 
work an existing apparatus that has been developed for the mentioned 
purpose has been adapted to comply with the requirements for the analy-
sis of low permeable compounds of BCS classes III and IV. Next to that, 
the apparatus was developed further in a way that the course of transepi-
thelial electrical resistance (TEER) could be recorded throughout conduc-
tion of an experiment. Implementation of this tool was supposed to provide 
for the opportunity to survey and demonstrate the integrity of a Caco-2 cell 
monolayer throughout an experiment. Furthermore, it was of interest to 
evaluate in how far the novel method was suitable for the analysis of the 
influences of excipients, as e.g. EDTA, on the permeability of the paracel-
lular pathway. Finally, it was pointed out that the revised apparatus is able 
to analyze Lasix® 40mg furosemide tablets correctly. Hence, the research 
approach has advanced significantly to the aim of the establishment of an 
in vitro method for the targeted formulation development of low permeable 
compounds. 
 
Zusammenfassung 
Zusammenfassung 
 
Die Messung der Freisetzung und der Permeation von Arzneistoffen aus 
festen Darreichungsformen zur peroralen Anwendung in einem kombinier-
ten Experiment ist ein naheliegender, bislang jedoch wenig behandelter 
Forschungsansatz. In der vorliegenden Arbeit wurde eine in einer voran-
gegangenen Arbeit zu diesem Zweck entwickelte Apparatur an die Erfor-
dernisse zur Analyse von langsam permeierenden Substanzen der BCS 
Klassen III und IV angepasst. Weiterhin wurde die Apparatur dahingehend 
weiterentwickelt, dass der Verlauf des transepithelialen elektrischen Wi-
derstandes während eines Versuches aufgezeichnet werden kann. Das 
Ziel dieser Maßnahme war es, die Prüfung der Integrität der Caco-2 Zel-
len, die in diesem Modell als Permeationsbarriere dienen, während eines 
Versuches zu ermöglichen. Daneben war es von Interesse zu untersu-
chen, inwieweit sich die neue Methode für die Analyse des Einflusses von 
Hilfsstoffen, wie beispielsweise EDTA, auf die Durchlässigkeit des parazel-
lulären Transportweges eignet. Abschließend konnte gezeigt werden, dass 
die optimierte Apparatur bei der Analyse von Lasix® 40 mg Furosemid Tab-
letten, als Beispiel für eine BCS Klasse IV Substanz, korrekte Ergebnisse 
liefert. Somit ist der Forschungsansatz dem Ziel der Entwicklung einer in 
vitro Methode zur gezielten Formulierungsentwicklung von Problemarznei-
stoffen ein wesentliches Stück näher gekommen. 
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Introduction 
1 Introduction 
1.1 Introduction into dissolution and permeation measurement 
1.1.1 Dissolution testing 
Dissolution testing of oral dosage forms has become a standard method in 
pharmaceutical quality control and formulation development since its 
introduction into the USP in 1968. The dissolution profile, primarily 
assessed in apparatus 1 or 2 USP, is a major characteristic of a marketed 
drug product. It is relevant for registration, batch release and represents 
an indicator for the suitable performance of the whole manufacturing 
process as well as for consistent product quality. With the introduction of 
the Biopharmaceutical Classification System (BCS) categorizing 
compounds according to their solubility and permeability into four groups 
(Table 1-1), the scientific basis for a further increase of the significance of 
dissolution testing was provided [1, 2]. The increase of knowledge, 
expanded in broad scientific discussions, provided the basis for the 
regulatory authorities to establish a legislation that allowed the granting of 
biowaivers for immediate release (IR) products of BCS class I compounds 
[3]. This concept stipulated that for compounds featuring a high aqueous 
solubility at a physiological range of pH and a high intestinal permeability 
(BCS class I) the account for bioequivalence studies may be waived. From 
a scientific point of view it was evident that in such cases a failure of an IR 
drug product in vivo can only be associated with a mistake in the 
pharmaceutical formulation leading to a delayed or incomplete release of 
the active pharmaceutical ingredient. To exclude such issues standardized 
dissolution testing was regarded as an adequate, efficient and sufficiently 
significant in vitro method. Furthermore, it seems to be evident that along 
with increasing in vivo relevance of the dissolution data, e.g. by application 
of biorelevant dissolution media, the potential significance of dissolution 
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testing in respect to drug product quality associated questions is not yet 
bailed out [4]. 
Class I 
Solubility:  high 
Permeability:  high 
Class II 
Solubility:  low 
Permeability:  high 
Class III 
Solubility:  high 
Permeability:  low 
Class IV 
Solubility:  low 
Permeability:  low 
Table 1-1 The BCS categorizes compounds according to the parameters solubility and 
permeability into four classes. 
A further area of research that is closely linked to dissolution testing is the 
establishment of in vitro - in vivo correlations. Here, it is aimed to elucidate 
an interconnection between the in vivo drug profiles obtained in small 
pharmacokinetic studies and a physicochemical property of oral drug 
formulations which in most cases will be represented by the dissolution 
profile [5]. If such correlations are available, bioequivalence studies may 
be waived if for example an intermediate dosage strength is supposed to 
be marketed or if small changes in the formulations have to be conducted. 
Once established, an IVIVC can be used in such cases to provide 
sufficient evidence for the expected in vivo performance only analyzing the 
dissolution profile of the new product. Not for all compounds it is likely that 
an IVIVC can be found. E.g. in the case of BCS class III compounds, 
featuring a permeation rate limited absorption, an IVIVC cannot be 
expected, as any difference in the dissolution properties of formulations 
will be levelled by the slow overall permeation of the drug. So, in general, it 
is only reasonable to look for a dissolution based IVIVC if the permeation 
is not the rate limiting step, as in this case it can be supposed that 
differences in the dissolution properties of formulations are reflected in the 
in vivo drug absorption. In this context combined measurement of 
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dissolution and permeation can be useful to obtain more significant IVIVCs 
using the in vitro permeation after a proceeding dissolution step as the 
most obvious parameter for correlation with the in vivo pharmacokinetic 
data [6]. Apart from that, BCS class III compounds provide further 
interesting discussions. The question is if for such compounds, showing a 
sufficiently high aqueous solubility in the range of pH 1.0 to pH 7.5, it is 
necessary to insist on bioequivalence studies e.g. for market authorisation 
of generics. As already explained, in such cases permeation of the solute 
drug molecules across the intestinal barrier is supposed to be the rate 
limiting step in the absorption process. So, applying the principles of BCS 
no significant differences between oral IR products are to be expected as 
long as the dissolution is very rapid (85% release within 30 min at pH 1.2, 
4.5 and 6.8). Therefore, the discussion about granting of biowaivers also 
for e.g. BCS class III compounds on the basis of results from dissolution 
testing appears to be quite reasonable [7-9]. Next to this BCS class III 
attributed point of discussion several further proposals to expand the 
legislation of the granting of biowaivers as e.g. the inclusion of IR 
formulations of weak acids categorized as BCS class II and soluble in 250 
ml at pH 6.8. [10-12]. The most well founded and broadly accepted 
approaches have been picked up in a WHO proposal which was supposed 
to allow waiving the account for in vivo BE studies of solid oral IR dosage 
forms of many APIs mentioned on the WHO model list for essential 
medicines [13]. This proposal included a revision of the criteria for BCS 
classification narrowing the pH window for high solubility to pH 1.2 – 6.8. 
Also the requirement for the status of high permeability was relaxed from 
formerly 90% to 85% absorption shifting some compounds that formerly 
were considered as BCS class III to class I. This document was adopted 
by the WHO expert committee on specification of pharmaceutical 
preparations. Thereby, the guideline provides recommendations for the 
authorities in charge of the approval of generic pharmaceutical products, 
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which are actualized to current scientific knowledge [14]. In context with 
growing knowledge about the impact of drug metabolism and transport a 
modification of the BCS called Biopharmaceutical Drug Disposition 
Classification System (BDDCS) was proposed [15]. In this concept the 
BCS parameter permeability was proposed to be replaced or extended by 
designation of the major route of drug elimination. In case of metabolism 
as the major route of drug elimination the compound would be regarded as 
highly permeable while in case of predominant renal or biliary excretion of 
unchanged drug it should be classified as low permeable. With application 
of > 90% metabolized as the cut-off criterion for high permeability next to 
the criterion of > 90% absorption, postulated by the BCS, the number of 
compounds assignable to BCS class I would be significantly enlarged. 
Finally, this concept would allow a broader application of biowaiver 
decisions based on metabolism [16]. So, it is evident that the efforts to 
illuminate the biopharmaceutical interrelations and the refinement and 
standardisation of in vitro methods will have to be prosecuted in order to 
minimize redundant human clinical studies and facilitate access to reliable 
and affordable medicines in developing countries. 
 
1.1.2 Permeation assessment 
The method of choice for intestinal permeation assessment that is suitable 
for classification of a compound according to the BCS is the determination 
of the extent that is absorbed in humans, which can either be performed 
as a mass balance or as a comparison to an intravenous reference dose 
[1, 2]. According to the original BCS guideline compounds showing an 
absorption of at least 90% are considered as highly permeable. Results 
from animal testing, especially using the in situ intestinal perfusion method 
in rats, are often considered as the number-two choice. Whereas 
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conformity between rat and man could not be found for the total 
bioavailability and comparing the expression levels of metabolizing 
enzymes, correlations for the intestinal permeability (R2 = 0.8) and 
moderate correlation for the expression levels of drug transporters (R2 > 
0.56) have been reported [17, 18]. Therefore, it can be concluded that the 
significance of the animal data is not necessarily higher than that obtained 
by in vitro permeation measurement. In an in vitro approach, the 
permeability of compounds can either be measured across biological 
barriers consisting of viable cells [19, 20], or across artificial membranes 
[21]. Whereas the basic mechanism underlying the models using artificial 
membranes is passive diffusion through the membrane material and the 
surrounding unstirred layers, the biological models are closer to the in vivo 
situation. Next to the availability of a transcellular and a paracellular 
pathway, those models also include mechanisms of active influx and efflux 
transport as well as intracellular enzymatic metabolism (Figure 1-1). 
Figure 1-1 Pathways and mechanisms of transport across small intestinal cells:  
(a) passive transcelluar transport by diffusion into and out of the cell; (b) active uptake 
followed by passive diffusion; (c) passive paracellular transport governed by the 
permeability of the tight junctions; (d) transcellular vesicular transport (transcytosis); (e) 
passive transcellular uptake followed by active apical efflux transport; (f) passive 
transcellular transport modified by enzymatic metabolism; (g) basolateral active transport 
(in- and efflux). 
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The biological models can be further subdivided into native tissue that has 
been excised from an organism or tissue that has been grown using cell 
culture technique. In general it can be said that the tissue originating from 
cell culture is less viable and robust as its native counterpart. On the other 
hand it features the significant advantage of containing no ethical conflicts 
which makes cell culture technology to an important branch of 
methodologies to realize the goals of the 3R concept, which is more than 
ever up to date [22]. In the practical approach, small intestinal tissue of 
rats is mounted in an Ussing chamber in order to determine the effective 
permeability (Peff). Good correlation (R2 = 0.95) between Peff in man, 
derived from in vivo data, and Peff values across rat intestinal tissue have 
been observed, although on an absolute scale the permeability in humans 
was 5 to 6 fold higher [23]. It was speculated that these differences could 
partly be explained by the lack of blood flow in the rat in vitro experiments. 
Apart from predicting human permeability the Ussing chamber model e.g. 
allowed revealing differences in the permeation rates in different intestinal 
regions of the rat [24]. The most widely used approach for permeation 
measurement across artificial barriers is the parallel artificial membrane 
permeability assay (PAMPA) first described by Kansy et al [25]. It is based 
on the 96 well scale allowing a high degree of automation and uses 
phospholipid coated Polyvinylidene fluoride (PVDF) filter membranes as 
permeation barrier. This approach by Hoffmann La-Roche attracted great 
attention in the pharmaceutical industry and was followed by the 
development of similar PAMPA approaches by other pharmaceutical 
companies. One of the critical points in this methodology was the discord 
of the best source for the initially used lecithin and its generally low degree 
of standardization. Therefore, Avdeef and coworkers developed an 
optimized coating containing Dioleyl-sn-glycero-3-phosphocholine (DOPC) 
instead of lecithin and further improved the method, e.g. by introduction of 
a pH gradient and a lipophilic gradient which was called the “Double-Sink” 
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PAMPA model [21]. Today, PAMPA which is suitable for automated high 
throughput screening and permeability measurement over Caco-2 cells 
have become standard methods in the early development of new APIs. 
Both methods provide complementary results and allow well substantiated 
conclusions about the presumable performance in humans. Regarding the 
apparatus for combined measurement of dissolution and permeation it is 
favourable to use a model that comes as close as possible to the original 
intestinal barrier in order to obtain the maximum in vivo relevance of the 
experimental data. Furthermore, the model should allow evaluating the 
interplay of excipients or the drug itself with transporter proteins and 
enzymes. At the moment these requirements are met best by the Caco-2 
cell model although it is well known that it does not mimic the small 
intestinal barrier perfectly [26]. A comparison of the relevant cell culture 
models can be found in chapter 1.3. Nevertheless, the option of an 
artificial membrane inside the FTPC would be advantageous as it e.g. 
allows studying the contribution of passive permeation to overall 
permeability. 
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1.2 Rational for the application of combined dissolution and 
permeation testing 
A major limitation for the development of new drugs is the often 
encountered and ever increasing issue of poor oral bioavailability of drug 
candidates detected in high throughput screening [27]. In consequence, 
the pharmaceutical industry faces the situation that an increasing number 
of compounds in the pipelines for small molecule development belong to 
BCS classes III and IV. These compounds share an intrinsic low 
permeability which is difficult to address. In case of BCS class IV, classical 
galenical approaches like micronization, preparation of solid solutions or 
microemulsions may be useful if the compound of interest is very lipophilic 
and features a dissolution rate limited absorption [28]. For larger and more 
hydrophilic compounds the mentioned galenical approaches will probably 
not be sufficient as in those cases permeation across the intestinal 
epithelium governs the overall absorption. Therefore, there is a keen 
interest in the finding and registration of suitable excipients increasing the 
intestinal permeability in man. Although over the years a lot of articles 
proposing a variety of compounds for such purposes have been published, 
only very few examples, like e.g. tocopheryl polyethylene glycol succinat 
(TPGS) in Agenerase®, have found their way into a marketed product. 
Another example is the concomitant application of 100 mg ritonavir as a 
booster of the pharmacologic effect of other protease inhibitors which is 
based upon the strong inhibition of mainly CYP 3A4 based metabolisation 
of protease inhibitors by ritonavir [29]. A major reason for the lack of 
application of classical permeation enhancers is the significant toxicity 
which in most cases is linked with a high efficiency of an enhancer. Lately, 
a systematic approach analyzing a variety of 51 enhancers from 11 distinct 
chemical groups in a standardized procedure focusing on the relationship 
of toxicity and potency was published [30]. In this study several excipients 
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that have been reported to comprise permeation enhancing properties but 
have not been in the focus of research up to now were shown to be 
effective without significant toxicity. In a second study the authors were 
able to point out synergistic effects applying a combination of up to three 
very potent excipients at low, nontoxic doses [31]. These studies 
demonstrate the high potential of excipients for permeation enhancement 
via the enteral route and encourage for further research with the most 
promising compounds in a more realistic approach, e.g. applying complete 
oral formulations containing excipients and a model drug. In this context 
the apparatus is the ideal means to bridge the gap between 96 well based 
approaches and in vivo pharmacokinetic studies, as it is specially 
designed for performance testing of complete oral dosage forms, thereby 
representing an in vitro tool to test and optimize novel formulation 
approaches. So, the determination and dosing of the ideal enhancer or 
combination of enhancers for an individual API might be performed using 
the apparatus minimizing the need for in vivo studies. 
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1.3 Caco-2 cells as a surrogate for the intestinal barrier 
Since its isolation from human colon adenocarcinoma tissue in 1977 Caco-
2 cells have become a well characterized and widely used model for the 
small intestinal epithelium [32, 33]. In pharmaceutical development 
analysis of Caco-2 cell permeability has become a standard method to 
estimate human absorption of new compounds and the cell line is routinely 
applied to screen a compound for affinity to intestinal active transporters 
[34-36]. Furthermore, Caco-2 cells find frequent application to study gut 
wall associated metabolism and toxicity [37, 38]. The high acceptance of 
the Caco-2 cell model as a surrogate for the small intestinal barrier can be 
explained by its physiological similarity to the native human epithelium and 
visualizing its singularities and advantages over other approaches. Having 
reached confluence Caco-2 cells spontaneously differentiate into an 
enterocyte typic phenotype with the formation of brush border associated 
microvilli as the most definite sign of apical and basolateral polarisation 
[39]. Along with the expression of functional tight junctions this habit was 
found to be maintained also after growing the cells on permeable supports 
which allowed conducting transport studies across Caco-2 cells [32]. 
Several studies pointed out good correlations between Caco-2 cell 
permeability and human intestinal absorption [17, 40-43]. The presence of 
the most important active transporters e.g. MCT1, PepT1 and OATP-B as 
well as efflux pumps like MDR1 (P-gp), MRP2 and BCRP was 
demonstrated suggesting the Caco-2 cell model as a tool to analyze the 
uptake mechanism of compounds and relative expression levels of these 
proteins were found to correlate with those of human intestinal epithelium. 
Nevertheless, smaller absolute levels of expression for some transporters 
like PepT1 and BCRP should be considered [44, 45]. In practical 
application the Caco-2 model revealed active transport or efflux for a 
variety of compounds, pointing out the significance of these mechanisms 
10 
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in the overall absorption process [46]. A further topic that stays in the focus 
of research is epithelial and hepatic drug metabolism. Caco-2 cells 
express a variety of metabolic enzymes, but CYP3A4, the enzyme that is 
responsible for the metabolisation of the majority of marketed compounds 
is expressed only weakly or not at all. Here, the induction of the gene by 
vitamin D3 or transfection of the cells with the CYP3A4 gene paved way to 
study the interplay of metabolism and efflux transport [38, 47-49]. But 
despite those approximations and similarities one should be aware that 
there are still notable differences between original human intestinal tissue 
and Caco-2 cells. A general drawback in comparison to excised tissue is 
the lesser robustness and vitality of cell culture models. Furthermore, 
native intestinal epithelial tissue is composed of two different cell types: 
ciliated cells and mucus producing goblet cells. Caco-2 cells are derived 
from ciliated cells and therefore the model does not feature a mucus layer. 
This mucus layer might be of relevance for intestinal drug absorption as it 
provides a pH gradient between lumen and cell surface which seems to be 
maintained by restricted diffusion of H+ ions secreted by the epithelial cells 
[50]. Direct measurement of the pH at the mucus layer with pH-
microelectrodes revealed a range of pH 5.8 to 6.3 in rat [51]. In order to 
account for the influence of the jejunal pH-microclimate the application of 
slightly acidic apical donor solutions of pH 6.0 was proposed [52]. Co-
culture approaches of Caco-2 cells and the mucus producing goblet type 
cell lines HT-29-H and HT29-MTX were established but did not yield 
sufficiently close approximation to the physiological conditions to 
compensate the additional work and expenses in contrast to Caco-2 cell 
monocultures [53, 54]. Intact Caco-2 cell monolayers feature higher TEER 
values and a generally less leaky paracellular barrier than native human 
intestinal tissue which might be attributed to the colonic origin of the cell 
line [33]. This correlates to the finding that rather hydrophilic drugs which 
are primarily absorbed via the paracellular route show lower permeability 
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in the Caco-2 model in comparison to humans [40]. In general it was 
shown that the predictive value of the Caco-2 cells for low permeable 
compounds is smaller than for high permeable compounds [55]. In this 
context the recently introduced 2/4/A1 cell line, originating from human 
small intestinal cells, was proposed as an alternative to study the 
permeation of passively absorbed drugs as it seemed to mimic the 
paracellular barrier better than the Caco-2 cells which e.g. manifested in 
lower, more physiologic TEER values below 100 Ω x cm2 [56]. Great interest 
has been devoted to the determination of the paracellular pore size which 
can be calculated from the permeation data of marker compounds using 
the Renkin molecular sieving function or analyzing the permeability of a 
series of PEG molecules to determine the cut-off molecular radius. Those 
data from different laboratories were re-evaluated recently using 
consistent input parameters suggesting a range of 4.0 to 12.9 Å for the 
paracellular pore size in unperturbed Caco-2 cell monolayers and a pore 
size of 17.8 Å for the 2/4/A1 cells line [57]. A recent study analyzing the 
permeability of different cell lines in comparison to human jejunal patches 
reported a biphasic permeability for Caco-2 cells and human intestine with 
nearly identical pore sizes and a monophase permeability for the 2/4/A1 
cells with a pore size of 14.9 Å. Therefore, the authors concluded that the 
known difference between paracellular permeability between Caco-2 cells 
and human small intestine might be ascribed to a lower pore density in the 
Caco-2 cell monolayers. Concerning the 2/4/A1 cells the authors 
supposed different paracellular permeation properties which raises 
questions about the previously postulated superiority of this novel cell line. 
Considering the purposes that the apparatus for combined measurement 
of dissolution and permeation has been developed for, the Caco-2 cell 
monolayer provides the most suitable cell culture model for the intestinal 
barrier at this moment. Due to the strong expression of efflux transporters 
it allows to evaluate performance testing of oral dosage forms containing 
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P-gp inhibitors incorporated into the drug formulation. Recently, the 
usefulness of TEER measurement to point out effective permeation 
enhancement with Caco-2 cell monolayer has been demonstrated [30]. 
So, also in the case of deliberate affectation of the tight junctions to obtain 
permeation enhancing effects, the Caco-2 cell model is very useful maybe 
even because it features higher TEER and a tighter paracellular barrier 
than human small intestinal tissue. Nevertheless, it could be useful to 
implement a CYP3A4 competent Caco-2 cell line in order to also study the 
influences of metabolism. Certainly, the ongoing research on the novel 
2/4/A1 cell line should be followed critically, as implementation of this 
human small intestinal cell line might become an option to maximize the in 
vivo relevance if a higher predictive value for low permeable compounds 
can be confirmed. Finally, the major drawback of the Caco-2 cell model, 
which can partly be assigned to the dynamic growth of research on this 
cell line should also be mentioned. It is the low level of standardisation of 
experimental procedures and protocols hampering the comparability of 
results from different laboratories and leading to significant interlaboratory 
differences that prevent the Caco-2 model from an even higher reputation. 
In order to improve this situation and strengthen the argumentation for in 
vitro cell culture models as a reliable substitute of in vivo studies, several 
efforts to pave way for a better standardisation of the model have been 
conducted in the last years [58-61]. 
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1.4 Starting point of the PhD thesis 
In a first PhD thesis, from 2004 to 2007, Stephan Motz developed the 
theoretical and practical basis for the combined assessment of dissolution 
and permeation using solid oral dosage forms [62]. At that time three 
interesting approaches had already bee described in the literature. In 1999 
Ginski and Polli published a simple continuous dissolution / Caco-2 
permeability setup that allowed prediction of the dissolution / absorption 
relationship in an in vitro experiment [63]. Using immediate and extended 
release formulations of three compounds belonging to different classes of 
the BCS the setup enabled to illustrate the differences in the oral 
bioavailability between dissolution- and absorption rate limited drugs 
absorption. Using the example of Piroxicam, a BCS class II compound, the 
authors demonstrated a switch from dissolution rate limited permeation for 
the extended release formulation to a permeation rate limited pattern when 
the immediate release formulation was tested. One major drawback of 
Ginski and Polli’s approach was that dissolution took place in a closed 
vessel, similar to apparatus 2 USP (rotating paddles). This resulted in a 
continuously increasing drug concentration on the donor side over time 
which is not in agreement to the physiological scenario of increasing and 
dropping gastrointestinal drug concentrations. In another approach 
published by Miyazaki and co-workers, however, this was improved using 
a flow through dissolution vessel and thereby applying an open system 
[64]. But the low flow rate in the dissolution module may limit the use of 
this setup for the application of complete oral dosage forms. A third 
approach by Kataoka and coworkers used a custom made side-by-side 
diffusion cell with a Caco-2 cell monolayer mounted in between [65]. An 
advantage of this system is its technical simplicity but on the other hand 
the approach is limited by the small apical volume which is available for 
dissolution and its character of a closed system similar to the approach by 
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Ginski and Polli. For a detailed depiction and analysis of the mentioned 
approaches for combined measurement of dissolution and permeation the 
reader is referred to the introductory chapter of Mr. Motz’s thesis [62]. In 
order to allow the analysis of complete solid oral dosage forms the 
apparatus developed at the Saarland University therefore features a 
compendial flow through dissolution cell (apparatus 4 USP) upstream the 
permeation module. This setup warrants an in vivo like situation of drug 
release and provides the basis for the design of the apparatus as a tool for 
advanced in vitro formulation development. 
 
1.4.1 Proof of concept with the BCS class I compound  
propranolol HCl 
After development of the apparatus its performance was tested using 
propranolol HCl immediate and extended release formulations. It was 
shown that the single components of the setup like stream splitter, pumps 
and the FTPC provided consistent and reproducible results. For 
propranolol tablets a total amount of approximately 0.35% of the apically 
offered drug permeated over the Caco-2 monolayer into the basolateral 
compartment [62]. Furthermore, dose linearity could be pointed out. 
Regarding the analysis of propranolol ER tablets, differences in the 
dissolution profile in contrast to the IR formulations had only a small 
impact on the overall permeation culminating in a value of approximately 
0.38% of the offered dose for a formulation containing 8% Eudragit® NE 
30D. In a second step an automation of sampling and detection was 
provided by installation of components for Sequential Injection Analysis 
(SIA) a further development of Flow Injection Analysis (FIA) [66]. In 
summary, propranolol HCl was a suitable compound to test the apparatus’ 
practical application and to perform a proof of concept study for the 
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combined measurement of dissolution and permeation of solid oral dosage 
forms. The major reasons for the choice of the compound were its 
unproblematic ADME parameters reflected in its categorization as a BCS 
class I compound. In general, it was necessary to analyse a BCS class I 
compound as a high permeability marker estimating the upper limit of 
permeation in the apparatus and evaluating the performance of the 
individual components of the setup. Only afterwards the analysis of low 
permeable compounds was sensible. 
 
1.4.2 Permeation of furosemide, a BCS class IV compound 
As a suitable compound for pointing out the benefits of combined 
measurement of dissolution and permeation, furosemide, a BCS class IV 
compound [67] was chosen. Next to its unfavourable physicochemical 
properties the compound showed asymmetrical transport across Caco-2 
cell monolayers suggesting that it is a substrate of an efflux pump [54, 62, 
68, 69]. Initial experiments with the marketed Lasix® 40mg IR tablet using 
a Sotax CE1 pump which generates a turbulent flow inside the dissolution 
module yielded a quick and complete release of the compound within two 
hours. The cumulative amount of furosemide that was detected at 
sampling port B reached 0.577% of the amount that was measured at the 
apical side which is rather high considering the results for propranolol as a 
high permeable drug, yielding a cumulative permeation of approximately 
0.35% [62]. Several potential reasons had already been excluded at that 
point of time including leakage of the FTPC and disruption of the Caco-2 
cell monolayer but the reason for the high permeability of furosemide 
remained unknown. Therefore, it was necessary to conduct a deeper study 
concerning the permeation of furosemide as a next step. This was 
considered to be an essential point and an urgent matter of research, as 
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the application of the apparatus will only offer its full value in the case of 
permeation rate limited drug absorption. In such cases effects taking place 
at the epithelial barrier like oversaturation of active transporters or the 
influence of excipients on efflux transport, drug metabolism or paracellular 
permeability gain in importance and may be crucial for the overall extent of 
drug absorption. As a precondition to analyze such phenomena the 
apparatus has to be able to pick up the results for the permeation of low 
permeable compounds correctly. 
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1.5 Aims of this thesis 
The first aim of the work was to enable the apparatus to measure low 
permeable compounds. Due to the unexpectedly high permeation of 
furosemide the performance of the compound inside and outside of the 
apparatus should be analyzed. Based on the results it should be clarified if 
the apparatus in its present form was suitable to study low permeable 
compounds or if it had to be adapted. 
After the apparatus had proven to pick up the permeation of low 
permeable compounds correctly it was aimed to focus on studies pointing 
out the benefit of combined measurement of dissolution and permeation 
over single dissolution or permeation assessment. Therefore, the effect of 
P-gp inhibitors like Tween 80 and TPGS which should be coadministered 
to the furosemide tablet should be studied. Due to the amphiphilic 
character of these compounds potential effects on dissolution were 
conceivable as well, making these excipients interesting candidates for 
formulation development of BCS class III and IV compounds. 
When this project was started, a feedback about the status of the Caco-2 
cell monolayer could only be obtained before and after conduction of an 
experiment as there was no access to the cell monolayer as soon as it 
was mounted inside the FTPC. This situation was considered as not 
sufficient and therefore it was intended to implement a tool to monitor the 
cell monolayer throughout conduction of an experiment. As a suitable 
method online measurement of Transepithelial Electrical Resistance 
(TEER) should be implemented inside the FTPC and its suitability to point 
out the cell monolayer integrity throughout the whole time of an experiment 
should be evaluated. 
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Next to the purpose of quality assurance, it should be evaluated if online 
TEER measurement was a suitable tool to analyze effects of formulation 
excipients upon the paracellular integrity of a Caco-2 cell monolayer. In 
this case online TEER measurement could be a valuable tool for advanced 
in vitro formulation development and provide a rational for the deliberate 
application of e.g. permeation enhancers to solid oral dosage forms. 
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2 Adaptations of the apparatus for the analysis 
of BCS class III and IV drugs 
2.1 Materials and methods 
2.1.1 Caco-2 cell culture 
Caco-2 cells, clone C2BBe1, were purchased at passage 60 from 
American Type Culture Collection (ATCC; Manassas, VA; USA) and used 
at passages 65-78. Cells were grown in T-flasks (75 cm2) at a temperature 
of approximately 37 °C in a humidified atmosphere containing 
approximately 5% CO2. Cell culture medium was changed every second 
day and consisted of Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal calf serum (FCS) and 1% non-essential 
amino acids (NeAA). At approximately 90% confluence cells were 
trypsinated and seeded on Transwell® permeable supports (Transwell® 
type 3460, Corning Inc., Acton, MA, USA) in a density of 60,000 cells/cm2. 
Transwell® supports were used for experiments after 21-25 days post 
seeding. 
 
2.1.2 TEER measurement 
Transepithelial electrical resistance (TEER) of the Caco-2 cell monolayers 
was measured with an EVOMX and handheld STX-2 electrodes (World 
Precision Instruments, Sarasota, FL, USA) before and after an experiment. 
The resistance of the blank permeable support was subtracted. 
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2.1.3 Buffer solutions and reagents 
Krebs Ringer Buffer (KRB) consisting of 1.41 mM CaCl2, 2.56 mM MgCl2, 
3.00 mM KCl, 142.03 mM NaCl, 0.44 mM K2HPO4, 4.00 mM D- Glucose 
and 10.0 mM HEPES adjusted to pH 7.4 was used as donor and acceptor 
medium. All salts for KRB preparation were of cell culture tested grade and 
obtained by Sigma Aldrich. Furosemide and propranolol HCl pure 
substances were obtained from Fagron (Barsbüttel, Germany). 
 
2.1.4 Sequential Injection Analysis 
Components for automation of the apparatus for combined measurement 
of dissolution and permeation consisted of a FIAlab 3500 (FIAlab 
instruments, Bellevue, WA), an autosampler (Cetac ASX 260, Omaha, NE, 
USA), an USB 2000 UV-Vis spectrometer and a D 2000 light source 
(Ocean Optics, Dunedin, FL, USA). The light source and the spectrometer 
were linked with a SMA Z-Flow Cell (Teflon®, 5 mm optical path length) for 
flow though absorption measurement with two fibre optic cables. 
Spectrometer settings and program codes can be found in chapter 6.3. 
 
2.1.5 Apparatus for combined measurement of dissolution and 
permeation 
At the beginning of the studies the apparatus was composed analogue as 
described in detail by Mr. Motz [62] and depicted in a schematic overview 
in (Figure 2-1). 
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Figure 2-1 Schematic depiction of the automated apparatus for simultaneous 
measurement of dissolution and permeation. Sampling ports are indicated with capital 
letters, D for Dissolution, A for Apical and B for Basolateral. The multiposition valve and its 
port assignment was as follows: Port 1 was connected with the waste, port 2 with the UV-
Vis detector, port 3 with the fluorescence detector (PMT-FL), port 7 was connected to the 
KRB supply for replenishing the volumes taken from the basolateral compartment. Port 8 
was connected to the autosampler for aspirating the standard solutions and filling of 
basolateral samples into HPLC vials. Ports 4, 5 and 6 are assigned to sampling ports D, A 
and B, respectively. 
 
2.1.6 Quantification of furosemide 
Furosemide was quantified using a Dionex UltiMate 3000 HPLC system 
consisting of a Dionex ISO-3100A pump, a Dionex WPS-3000 TSL 
autosampler, a Dionex VWD-3400 variable wavelength detector, a Dionex 
TCC-3000 column compartment and a Dionex SRD-3200 solvent rack. A 
RP 18 column (LiChroSpher® 100, Merck) 5 µm, 12.5 cm was 
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implemented and the HPLC was run on Chromeleon software version 6.80 
SP2 build 2284. The mobile phase consisted of 60% water (v/v), 30% 
acetonitrile (v/v), 10% methanol (v/v), 0.033% triethylamine (v/v) and 
0.044% phosphoric acid (v/v). The flow rate was set to 1.2 ml/min, the 
temperature of the column oven was adjusted to 40 ± 1 °C and the 
wavelength for furosemide detection was set to 235 nm. Retention time 
was 3.02 min ± 0.04 min. It was shown that neither the matrix of KRB nor 
the excipients of the tablets interfered with the analysis. 
 
Figure 2-2 Calibration line for furosemide using described HPLC method. 
Calibration was linear (R2 > 0.9999) in the range of 25 – 4000 ng/ml. The 
slope of the calibration line was 3.425 ± 0.017 and the offset was 
calculated as -0.0044 ± 0.0047. LOD was determined as 0.007 ± 0.001 
µg/ml and LOQ was determined as 0.018 ± 0,007 µg/ml. Both parameters 
were calculated based on the residual standard deviation and the slope as 
recommended in ICH Q2 (R1) guideline. 
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Figure 2-3 The figure shows an excerpt of the calibration line for furosemide showing the 
lower concentrations of the standards. 
 
2.1.7 Quantification of sodium fluorescein 
For quantification of sodium fluorescein in 96 well plates a Cytofluor II 
fluorescence reader was used (λexc = 485 nm, λem = 530 nm), (PerSeptive 
Biosystems, Wiesbaden-Norderstedt, Germany). Linearity (R2 > 0.999) 
was ensured between 5 ng/ml and 1 µg/ml. 
 
2.1.8 Quantification of rhodamine 123 
For quantification of Rhodamine 123 in 96 well plates a Cytofluor II 
fluorescence reader was used (λexc = 485 nm, λem = 530 nm), (PerSeptive 
Biosystems, Wiesbaden-Norderstedt, Germany). Linearity (R2 > 0.999) 
was ensured between 4 ng/ml and 0.2 µg/ml. 
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2.2 Case study with furosemide 
2.2.1 Introduction 
After successful measurement of propranolol HCl IR and ER formulations 
it was aimed to evaluate the eligibility of the apparatus also for low 
permeable compounds of BCS classes III or IV. Initial results with 
furosemide, a BCS class IV compound, yielded a fairly high permeation, 
which was even higher than for the high permeable compound 
propranolol. So the study of this topic was regarded as an urgent matter of 
research as the option to analyze low permeable compounds is a 
prerequisite for the reasonable application of the apparatus in successive 
studies. First questions that were arising were if the phenomenon was 
linked with the compound itself or with the apparatus. To clarify this, the 
permeation of furosemide was analyzed in two surroundings, the 
Transwell® setup and the apparatus. 
 
2.2.2 Permeation in the Transwell® setup 
Initial experiments were conducted outside of the FTPC in the Transwell® 
system in order to analyze the permeation patterns of furosemide under 
standardized conditions. As can bee seen in Figure 2-4 the drug 
permeated linearly across Caco-2 cell monolayers after application of 
200 µg/ml, 500 µg/ml and 1000 µg/ml furosemide donor solutions in the 
apical compartment. 
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Figure 2-4 The graphs show the permeation of furosemide over Caco-2 cell monolayers 
at different donor concentrations in the Transwell® setup (n = 3). 
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Mean apparent permeability was calculated from the slope of the curves 
according to Equation 2-1 as 1.11 ± 0.08 x 10-6 cm/s, 1.75 ± 0.02 x 10-6 
cm/s and 3.08 ± 0.28 x 10-6 cm/s. 
d
app cA
1  
dt
dQP ××=  Equation 2-1 
The experiments pointed out that the apparent permeability tended to rise 
with increasing donor concentrations. Next to the already mentioned 
asymmetrical transport of furosemide across Caco-2 monolayers this 
finding further supported the assumption that furosemide is subject to 
apical efflux transport. The status of saturation of an efflux transporter is 
supposed to be dependent on the donor concentration which influences 
the apparent permeability coefficient. So, a decreasing influence of the 
efflux transport with increasing substrate concentration can be expected, 
which is very similar to a Michaelis-Menten kinetic. 
c Donor [µg/ml] Papp [cm/s] 
5 0.67 ± 0.20 x 10-6
10 0.84 ± 0.01 x 10-6
100 0.72 ± 0.08 x 10-6
200 1.11 ± 0.08 x 10-6
400 1.68 ± 0.05 x 10-6
500 1.75 ± 0.02 x 10-6
1000 3.08 ± 0.28 x 10-6
Table 2-1 Apparent permeability coefficients (Papp) calculated from the linear part of the 
permeation curves shown in Figure 2-4. 
After analyzing additional donor concentrations of 5 µg/ml, 10 µg/ml, 100 
µg/ml and 400 µg/ml (Figure 2-4), the assumption of a dependency 
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between donor concentration and apparent permeability was confirmed 
(Figure 2-5). An overview of the calculated Papp values can be found in 
(Table 2-1). Within the range of concentrations that were analyzed, a linear 
(R2 = 0.98) concentration dependency was found supposing that the 
concentration for saturation for the efflux transport is considerably higher 
than 1000 µg/ml (Figure 2-5). 
 
Figure 2-5 Dependency of the apparent permeability from the furosemide donor 
concentration. 
But as this topic was not the most urgent matter of research, no further 
experiments were done here. Visualizing these results it was concluded, 
that the absolute level of donor concentrations might have an influence on 
the overall extent of permeation and thereby the partially saturation of 
efflux transport may contribute to the unexpectedly high permeation of 
furosemide within the apparatus. On the other hand, it had to be 
considered that with 2.5 x 10-5 cm/s [62] the apparent permeability of 
propranolol was still approximately ten times higher as that obtained for 
the highest donor concentration of furosemide. Furthermore, analyzing 
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tablets in the apparatus, high donor concentrations are effective only for 
the time when the peak concentration of the released compound is 
reached. In conclusion it is unlikely that the partially saturation of efflux 
transport by high donor concentrations of furosemide was the major 
reason for its unexpectedly high permeation. 
 
Figure 2-6 Permeation of furosemide over blank Transwell® supports at three different 
donor concentrations (n = 3). 
As a control, experiments with blank Transwell® supports were conducted, 
clearly demonstrating that the filter membrane does not pose a significant 
hindrance for drug permeation (Figure 2-6). A non linear behaviour was 
obtained due to a quick depletion of the donor concentration leading to 
non sink conditions. 
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2.2.3 Permeation in the apparatus 
The performance of Lasix® 40 mg IR tablets in the apparatus was 
evaluated in three experiments. The graph supposed a rapid accumulation 
of the drug in the basolateral compartment with a following depletion over 
time which was unexpected, as the apparatus featured a closed 
basolateral compartment (Figure 2-7). 
 
Figure 2-7 Basolaterally measured amount of furosemide after dissolution of Lasix® 
tablets at the donor side. 
A back diffusion of the drug as a potential reason for the depletion of 
furosemide from the basolateral compartment was regarded as highly 
unlikely, as the absolute concentrations measured at the apical side were 
consistently higher as those measured in the basolateral compartment 
throughout the whole time of the experiments. Drug release from the 
Lasix® tablet was incomplete applying a membrane dosage pump with a 
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pulsation absorber as dissolution pump. Under those conditions providing 
a laminar flow inside the dissolution cell the compound was not dissolved 
completely which might be primarily addressed to the fact that the 
compound shows severe wetting issues next to the fact that the Lasix® 
formulation lacks in a modern “superdisintegrant” as e.g. cross-linked 
polyvinylpyrrolidone or cross-linked sodium carboxymethylcellulose 
(Figure 2-8). 
 
Figure 2-8 Apical concentrations analyzing Lasix® tablets with the apparatus as pointed 
out in Figure 2-1 (n = 3). 
In order to reduce the number of variables and allow better comparability 
to the situation in the Transwell® setup, furosemide donor solutions 
providing a constant concentration on the apical side were analyzed 
instead of the tablets. Similar to the results that were obtained with the 
tablets high initial amounts of drug were detected at the basolateral port 
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(Figure 2-9). For the rest of the time the drug amount increased slightly but 
this did not happen in a linear way as would have been expected. 
 
Figure 2-9  Amounts of furosemide measured at the basolateral side after application of 
donor solutions (c = 200 µg/ml) did not show a linear trend (n = 2). 
Sorption of the compound to an internal surface of the basolateral 
circulation was considered as a potential reason that might explain the 
undulating behaviour of the basolaterally measured amount of drug. 
Polyetheretherketon (PEEK), the material that e.g. the basolateral vessel 
consists of, was excluded as a potential originator (data not shown). The 
remaining critical surfaces like peristaltic pump tubing and the interior of 
the pulsation absorbers were more difficult to analyze. In comprehensive 
experiments, furosemide solutions were pumped within the basolateral 
circulation and samples that were taken manually from the basolateral 
vessel revealed undulating concentrations within this compartment. 
Although these experiments could not definitely clarify if the 
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inhomogeneous concentrations found in the basolateral compartment had 
to be attributed to sorption issues or insufficient mixing the finding led the 
focus for troubleshooting on the basolateral compartment. 
2.2.3.1 Simplified basolateral conditions 
Furosemide permeation was measured in a simplified basolateral 
surrounding, as it was suspected that the non linear permeation behaviour 
of furosemide in the FTPC might be attributed to the basolateral 
compartment. Waiving the complete basolateral circulation, the setup was 
put into an apically dynamic and basolaterally static situation. 
Experiment No. TEER before experiment [Ω x cm2] 
TEER after 
experiment [Ω x cm2] 
1 477 310 
2 504 407 
3 449 468 
4 477 534 
Table 2-2 TEER of Caco-2 cell monolayers measured before and after conduction of 
experiments with simplified basolateral conditions. 
Consequently, the basolateral vessel, the standard sampling point on the 
receiver side, was not hooked up and therefore the samples were drawn 
directly from the basolateral cavity of the FTPC using a syringe. These 
experiments were conducted without application of a counter-pressure 
from the basolateral side, as no pump was installed. Caco-2 cells were 
checked microscopically and proofed to be intact before and after the 
experiments which was also confirmed by TEER measurements (Table 
2-2). In this setup, that circumvented the basolateral circulation and limited 
the volume of the acceptor compartment to the space inside the 
basolateral cavity of the FTPC, furosemide permeated linearly across the 
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Caco-2 cell monolayers (Figure 2-10). Therefore, the strange permeation 
behaviour that was found before was attributed to the basolateral 
circulation and consequently it was decided that the basolateral 
compartment should be revised. 
 
Figure 2-10 Permeation of furosemide in the FTPC under simplified basolateral 
conditions. Papp was calculated to 0.47 ± 0.10 x 10-6 cm/s for n = 4 experiments. 
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2.3 Revision of the basolateral compartment 
The original basolateral compartment featured a transfer cycle driven by a 
membrane dosage pump and a measurement cycle driven by a peristaltic 
pump (Figure 2-11). One drawback was seen in the multiple subdivisions 
of the compartment rising questions about the homogeneous distribution 
of the accumulating drug inside the acceptor buffer. Secondly, the usage of 
peristaltic tubing was considered as critical, due to potential sorption and 
migration issues of lipophilic compounds. 
 
Figure 2-11 The original basolateral compartment featuring a transfer cycle driven by a 
membrane dosage pump and a measurement cycle driven by a peristaltic pump. 
Due to the promising results that were obtained with the FTPC using a 
basolaterally static compartment, this approach was taken as a starting 
point for the reconstruction of the basolateral compartment. So, it was 
regarded as favourable to limit the compartment to the space of the 
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basolateral cavity of the FTPC itself. As this scenario no longer featured a 
flow through environment, a magnetic stirrer was integrated to provide a 
homogeneous distribution of the drug in the acceptor buffer. Therefore, the 
space of the basolateral cavity had to be enlarged slightly. Nevertheless, a 
reduction of the overall volume of the basolateral compartment from 
formerly 5.5 to now 3.8 ml was yielded. The basolateral pump with 
pulsation absorber, the interconnecting peristaltic tubing and the 
basolateral vessel could be waived (Figure 2-12). 
 
Figure 2-12  Schematic depiction of the revised basolateral compartment, limiting the 
acceptor volume to the space of the basolateral cavity of the FTPC. 
A detail drawing of the FTPC after revision can be seen in Figure 3-1. By 
means of these adaptations the above-mentioned questions could be 
dispelled and in addition a simplification of the handling was reached. 
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2.4 Hydrostatic pressure compensation between apical and 
basolateral side of the FTPC 
Caco-2 cells grown on permeable supports are sensitive to pressure 
differences between the two compartments. Especially pressure from the 
basolateral side has to be avoided, as this may lead to a detachment of 
the cells from the supporting membrane. In the original setup equal 
pressure weighing on both sides of the cell monolayer was warranted by 
symmetrical installation of two membrane dosage pumps providing equal 
flow rates through the apical and the basolateral cavity of the FTPC. 
 
Figure 2-13 The necessary basolateral counter pressure to the apical flow can be 
determined without installation of a Transwell® inside the FTPC. The liquid column at the 
basolateral KRB supply will adjust to a height that provides a corresponding hydrostatic 
counter pressure to the apical flow. After equilibration the height of the suitable liquid 
column can be read out and will provide apical to basolateral pressure balance in 
experiments with a Caco-2 cell monolayer mounted between the compartments. In this 
setup replenishment of the sample volumes with blank KRB is provided automatically. 
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In the revised setup the basolateral pump was waived and pressure 
balance was reached applying a suitable hydrostatic counter-pressure 
from the basolateral side (Figure 2-13). Therefore, the tube of a 100 ml 
syringe was filled with KRB, fixed inside the water bath and connected with 
the FTPC by means of polymeric tubing. 
 
Figure 2-14 TEER of Caco-2 cell monolayers before insertion into and after 2 hours 
inside the FTPC. 
To determine the necessary counter pressure, the FTPC was assembled 
without insertion of a Transwell®, the internal space was prefilled with KRB 
and the apical pump was switched on. The meniscus of the liquid column 
inside the basolateral KRB supply, was read after equilibration of the 
system as 14.0 ml above the bottom level of the FTPC. This level was 
adjusted in experiments comprising Caco-2 cells. TEER measurement 
before and after the experiments revealed that this procedure provided a 
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suitable pressure compensation which was not inferior to the method 
applied in the original setup (Figure 2-14). 
 
2.5 Influence of automated sampling on permeation results 
After revision of the basolateral compartment the application of a donor 
concentration of 200 µg/ml resulted in a lower linearity of the permeation 
as obtained in the preceding experiments with the reduced basolateral 
compartment and manual sampling (Figure 2-15). 
 
Figure 2-15 Basolateral permeation of furosemide after application of 200 µg/ml donor 
solutions with the new basolateral compartment (n = 3). 
Nevertheless the calculated Papp of 1.34 ± 0.10 x10-6 cm/s corresponded 
to the results that were obtained in the Transwell® setup (Table 2-1). After 
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studying the donor solutions the performance of the apparatus using 
Lasix® tablets was evaluated revealing that the results were still not as 
expected (Figure 2-16). Especially the decreasing amount of furosemide 
measured at sampling point B cannot be explained as the setup after 
revision is still built up as a closed compartment and therefore an 
accumulation of the drug was expected. 
 
Figure 2-16 Basolateral amount of furosemide after analysis of Lasix® 40 mg IR tablets  
(n = 5). 
So, further efforts to solve these questions had to be taken. In order to 
clarify if the drug measured at point B really took the way across the Caco-
2 cell monolayer an impermeable Transwell® with pores that were sealed 
with varnish was used in the successive experiments. To simplify the 
detection in the following experiments propranolol donor solutions instead 
of furosemide solutions were used as in this case online detection was 
feasible at all three measurement points, whereas analysis of the 
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basolateral samples of furosemide required HPLC analysis. This was 
possible as the question that should be addressed was not depending on 
the nature of the compound. Using a 60 µg/ml propranolol donor solution a 
basolateral signal was observed, although the connection between the 
donor and the acceptor compartment was sealed (Figure 2-17). 
 
Figure 2-17 Fluorescence signals measured in the revised setup at sampling port D (●), 
A (○) and B (▼) using an impermeable Transwell® support and a propranolol donor 
solution. 
After this important finding two more possibilities were conceivable. Either 
there was a leakage between the impermeable Transwell® and the O-ring 
inside the FTPC or the basolateral signal dated from a separation issue at 
the multiposition valve. This question could be clarified in a second 
experiment plunging the tubing for aspiration of basolateral samples into a 
vessel containing blank KRB. In this experiment an identical result as in 
the first one was obtained (Figure 2-18) which allowed the conclusion that 
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the conflicting results can only be ascribed to a problem at the 
multiposition valve. 
 
Figure 2-18 Fluorescence signals measured in the revised setup at sampling ports D (●) 
and A (○) applying a 60 µg/ml donor solution and aspirating blank buffer at measurement 
point B (▼). 
 
2.6 Test routine for SIA valves 
The findings of the experiments using an impermeable Transwell® 
indicated that the problem was located at the multiposition valve. In order 
to quantify the carry-over between the individual ports of the 8 port SIA 
valve a test routine was developed and a simple experiment using two 
sampling ports, one blank and one propranolol solution was performed. 
The SIA was programmed to sample alternately at two neighbouring ports. 
When both ports took their samples out of the blank, no fluorescence 
42 
Adaptations of the apparatus for the analysis of BCS class III and IV drugs 
signal was detected. When one of the ports took its sample out of the 
vessel containing the drug solution and the other still out of the blank, 
there was a signal detectable at the port that only aspirated blank buffer 
(Figure 2-19). 
 
Figure 2-19 Fluorescence signals obtained during alternating sampling at 2 neighbouring 
ports. During the times that now signal was retrieved both ports took their samples from a 
blank solution. Signals were detectable at both ports, when one port was sampling blank 
buffer and the other port a propranolol solution. 
This proofed that the multiposition valve was not able to separate samples 
from different ports completely. After consultation of the SIA manufacturer 
(FIAlab instruments, Sarrasota, FL) on those results it was decided to 
renew the 8 port valve in order to warrant the optimum performance of the 
setup. After mounting of the replacement valve the experiment was 
repeated and a better, but still incomplete separation was obtained. 
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Further experiments pointed out that the intrinsic carry-over of the valve 
lies between 0.5 and 1% (Figure 2-20). 
 
Figure 2-20 Determination of the carry-over between 2 neighbouring ports after 
installation of a new 8 port multi position valve. 
This bias is tolerable for the analysis of high permeable compounds, like 
propranolol. Here, a drug concentration of approximately 5% of a constant 
donor solution after two hours can be expected (Figure 2-21). That means 
that the bias of the carry-over effect is surmounted already 20 minutes 
after start of the experiment and therefore it was regarded as negligible. 
For the analysis of low permeable compounds the situation is different. 
Due to the low flux over Caco-2 monolayers the basolateral concentration 
increases slowly. Calculating the basolateral concentrations of a 
compound with a Papp of 5 x 10-7 cm/s after two hours with a constant 
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donor concentration and an acceptor volume of 3.8 ml a value of less than 
1% of the donor concentration has to be expected. That means that in this 
case the bias of the carry-over effect does not allow measuring the 
permeation rate of such a compound simultaneously to the concentration 
at the donor side. 
 
Figure 2-21 Concentration time trend of propranolol donor solutions (c = 20 µg/ml) at the 
apical and the basolateral sampling point (n = 3). 
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2.7 Implementation of an independent route for basolateral 
sampling 
Simultaneous sampling of high concentrations at ports D and A next to the 
analysis of low concentrations at port B using only one multiposition valve 
turned out to be impossible due to an intrinsic carry-over biasing the 
results for the low concentrations. 
 
Figure 2-22 The figure shows a schematic overview of the revised apparatus featuring 
the dissolution module, the permeation module and a third module for automation using 
Sequential Injection Analysis (SIA). Dissolution takes place in a compendial flow through 
cell (Apparatus 4 USP). Samples of the high concentrations right behind the dissolution 
cell and at the outflow of the apical compartment are taken via an 8 port multiposition 
valve and analyzed online using an UV-VIS spectrometer or a fluorescence detector 
(PMT-FL). Samples of the acceptor compartment are taken via an additional 6 port valve 
and analysis is done offline in a plate reader or by means of HPLC measurement after 
bottling with an autosampler. 
As it turned out to be technically impossible to circumvent that carry-over 
effect with the existing equipment it was decided to install a separate route 
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of sampling for the basolateral compartment. Therefore, a second syringe 
pump, a 6 port valve and an autosampler were installed. A schematic 
overview of the automated setup can be seen in Figure 2-22. 
2.8 Performance test of the revised apparatus 
After revision of the basolateral compartment and installation of an 
independent route for basolateral sampling the setup was tested with the 
marker compounds sodium fluorescein and rhodamine 123 using 
fluorescence detection (λex = 485 nm, λem = 530 nm). 
 
Figure 2-23 Permeation of sodium fluorescein (▼ continuous line) and rhodamine 123  
(▼ dotted line) in the revised setup after installation of an independent route for 
basolateral sampling using donor solutions. Simultaneously to the permeation 
transepithelial electrical resistance (TEER) was recorded in the FTPC as a measure for 
the status of the paracellular barrier of the Caco-2 cells (see chapter 3). 
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After application of constant donor concentrations on the apical side, a 
linear permeation for 3.5 hours was observed for both compounds (Figure 
2-23). Papp was calculated to 1.4 x 10-6 cm/s for rhodamine 123 and to 4.0 
x 10-7 cm/s for sodium fluorescein. Troutman and Thakker reported a 
permeability of 1.5 x 10-6 cm/s [70] for rhodamine 123 and for sodium 
fluorescein Papp values ranging from 2.1 – 6.23 x 10-7 cm/s have been 
reported [71-74]. So, the permeability of the marker compounds is in good 
agreement to the values reported in the literature pointing out the 
suitability of the revised setup for the analysis of low permeable 
compounds. When these experiments were conducted the FTPC was 
already implemented with electrodes for measurement of TEER which 
therefore was recorded simultaneously to the permeation assessment 
(Figure 2-23). TEER remained on a high level for approximately 3.5 hours 
pointing out the time span of cell monolayer integrity. Only when TEER 
dropped to low values, permeation rate of sodium fluorescein and 
rhodamine 123 increased strongly. The remaining question about the 
analysis of furosemide oral formulations is discussed in chapter 4. 
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3 Online TEER measurement 
Parts of this section have been published in: 
Muendoerfer, M., et al., Online monitoring of transepithelial electrical 
resistance (TEER) in an apparatus for combined dissolution and 
permeation testing. Int J Pharm, 2010. 392(1-2): p. 134-40. 
 
3.1 Rational for the implementation of online TEER measurement 
Two major benefits were aimed for by means of developing a feature for 
online TEER measurement inside the apparatus for combined 
measurement of dissolution and permeation. First of all there was an 
urgent need for a tool that provided feedback on the status of the cell 
monolayer inside the FTPC during the course of an experiment. Prior to 
that, it was only possible to analyze a cell monolayer before and after an 
experiment outside the FTPC. This was considered as insufficient as e.g. 
handling of the cells and change of buffer solutions causes temperature 
drops which are well known to influence TEER [75]. Therefore, online 
TEER measurement should serve as a tool for surveillance of the cell 
monolayer and was supposed to be a means for in-line control supporting 
the results of each experiment. In addition to that the novel feature should 
be tested for its suitability as a tool to analyze the effects of excipients on 
cell monolayer permeability. In this context it was supposed that online 
TEER measurement might be a valuable improvement of the apparatus 
regarding its scope as a tool for the advanced formulation screening of 
BCS class III or IV compounds. 
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3.2 Introduction into TEER measurement 
3.2.1 TEER and tight junctions 
Measurement of TEER is a well established method for the non-
destructive and non-invasive monitoring of the barrier status of cellular 
layers grown on permeable supports. As long as in this case the Caco-2 
cells have not reached confluence TEER stays at a low level, close to the 
blank resistance of the permeable support. Only after the epithelial cells 
reach confluence they stop proliferation and start to differentiate. This gets 
visible in a polarization of the cells into an apical and a basolateral side. 
Next to that it comes to the formation of the so called tight junctions 
between neighbouring cells [39]. These protein based structures surround 
the lateral sides of the cells in the upper third, close to the apical end in a 
belt-like shape. Completely developed, the tight junctions seal the cellular 
interspaces and provide the rate limiting barrier for the passive paracellular 
transport of solutes [76, 77]. The mesh-like structure formed by individual 
protein strands can be visualized in freeze fracture replicas [78]. This 
method also allows pointing out the fence function of the tight junctions. 
After application from the basolateral side, macromolecules as horseradish 
peroxidise or haemoglobin diffuse freely along the paracellular interspaces 
until reaching the tight junctional strands [79]. Electrophysiological 
characterization of epithelial cell monolayers revealed junctional charge 
and size-selectivity and allowed the determination of the pores, formed by 
the tight junctions to be mainly permeable to sodium ions [80]. According 
to the latest findings on the molecular assembly of the tight junctions these 
structures are composed by protein clusters of the Claudine family [81, 
82]. These proteins feature two extracellular domains carrying either 
negative or positive excess charges according to the individual distribution 
of acidic or basic amino acids. In a potential spatial model these protein 
aggregates are supposed to build pores with charged internal linings 
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conveying the well known charge and size restriction for paracellular 
solute transport. 
 
3.2.2 Practical approaches for TEER measurement 
TEER measurement is usually performed as single point measurement at 
certain points of time for example during the period of cellular growth in 
order to monitor the maturation of the cells of interest. In this case the 
measurement has to be conducted under sterile conditions inside a 
laminar flow box. During cellular growth the confluence of the cells to a 
monolayer is pointed out by an increase in TEER and the magnitude of 
TEER correlates with the tightness and impermeability of the cellular layer. 
The absolute level of TEER that a cell monolayer can reach is a cell type 
characteristic feature. The Caco-2 C2BBe1 clone in our lab typically 
reaches a value of > 400 Ω x cm2 as soon as the cells have been 
passaged for the first few times after thawing. Nevertheless a broad range 
of TEER values for Caco-2 cells can be found in the literature spanning 
from 80 up to 1420 Ω x cm2 [83]. Reasons for this high variability may be 
found in different subclones, passage numbers and cultivation protocols of 
the cells. 
TEER measurement can be performed in different ways: 
1) Measurement with hand-held electrodes 
The standard in cell culture associated TEER measurement is the single 
point measurement of TEER after insertion of a so called “chop-stick” 
electrode, (e.g. STX-2 electrode, World Precision Instruments, Sarasota, 
FL, USA) into the apical and the basolateral part of a multi-well culture 
plate with a cellular layer grown on top of a permeable support (e. g., 
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Transwell®, Corning Inc., NY, USA). Chopstick electrodes feature specially 
designed shanks so that after insertion into the well plate a direct contact 
between the apical electrode and the cellular layer is prevented. The 
readout of the resistance might for example be done with an EVOM2 
(WPI, Sarasota, FL, USA) or the Millicell ERS-2 Epithelial Volt-Ohm Meter 
(Millipore, Billerica, MA, USA). 
2) Measurement in Endohm chambers 
Next to the use of hand-held electrodes it is also common to check TEER 
of a cell monolayer with a fixed set of electrodes inside a so called 
Endohm chamber (WPI) into which the permeable support has to be 
transferred into right before the measurement. This option features the 
advantage of a lower background resistance due to the optimized position 
of the electrodes and it also reduces the variability of the resistance 
readings. A disadvantage of this method is the necessity to transfer the 
permeable support from the experimental environment into the Endohm 
chamber and the need to replenish the apical and basolateral liquid 
volumes which is known to influence the absolute value of TEER [75]. 
3) Automated measurement of TEER in well plates 
Furthermore, it is possible to measure TEER of monolayers grown on 
individual permeable supports inside one bottom plate in an automated 
way. Therefore, the well plate containing the permeable supports has to be 
handed over to an autosampler featuring an electrode fixed with a robotic 
arm, which allows sequential measurement of TEER of individual 
monolayers in combination with a computer control unit (REMS system; 
WPI). 
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4) Measurement of electrical resistance in non-cell based assays 
Apart from cell culture associated TEER measurement it is also common 
to measure the electrical resistance of artificial membranes incorporated 
into well plates and intended for the high-throughput permeability 
screening of solutes after conduction of the respective experiment in order 
to check the integrity of the artificial membrane. This can for example be 
performed with the EVOM2, a hand held top electrode and WPI’s Multi-96 
bottom plate containing basolateral electrodes. 
5) TEER measurement during cultivation of cell monolayers on 
permeable supports 
A device for the measurement of transepithelial impedance and TEER of 
cell layers grown on permeable supports throughout the period of growth 
is commercially available (“cellZscope”, nanoAnalytics GmbH, Münster, 
Germany). This product consists of a cell module which is placed inside an 
incubator, an external controller unit and a software as user interface. 
Further information to this approach can be found by Wegener et al. [84]. 
 
3.3 Realisation of TEER measurement inside the FTPC 
As a first step towards online TEER measurement electrodes had to be 
installed inside the apical and the basolateral brick of the FTPC. As 
voltage sensors sintered silver-silver chloride bare sensor electrodes (In 
vivo Metric, Healdsburg, CA, USA) were chosen and as current electrodes 
pure silver wire has been used which from the choice of electrode-
materials corresponds to the commercially available handheld STX-2 
electrode (WPI). In detail, drillings have been added to the apical and the 
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basolateral brick of the FTPC that allow for the necessary wiring and the 
seamless implementation of the electrodes into the inner surface of the 
FTPC (Figure 3-1). At the outside of the bricks screw ports with 1/4-28 
threads for connection with flangeless fitting adapters, made of PEEK, the 
identic material as used for the FTPC itself, have been integrated. These 
adapters were custom made at BESTA-Technik für Chromatographie 
GmbH, 69259 Wilhelmsfeld, Germany (Figure 6-1). The adapters serve as 
spacers for plugging in the cables to the EVOMX and provide a proper 
sealing against intrusion of water from the surrounding water bath. In the 
heads of these adapters plugs with M5 screw threads that are connected 
to the internal wiring have been mounted. Inside the adapters the wiring is 
led through a peace of 1/16’’ polymeric tubing which is tightened by means 
of a flangeless ferrule at the moment that the adapter is screwed in. To 
prevent a leakage line between wire and polymeric tubing, the wire has 
been sealed inside the tubing by means of a drop of superglue. At the 
 
Figure 3-1 Detail drawing of the FTPC after revision of the basolateral compartment and 
implementation of electrodes for continuous TEER measurement. 
basolateral brick the electrodes have been integrated into the backplane of 
the interior cavity. At the apical brick it turned out to be superior to mount 
the electrodes into the front tip instead of the backplane of the body, as 
hereby a lower background resistance and a better stability of the signal 
could be retrieved. This can be explained by the fact that this configuration 
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features a smaller distance between the electrodes and a more symmetric 
adjustment with regard to the cell monolayer. In this configuration the 
stream-lines of the electrical field are crossing the cell monolayer in 
rectangular direction without disturbance of any material of the PEEK 
housing (Figure 3-1). 
 
3.4 Proof of principle using analogue recording 
After hooking up the electrodes and connection of a writer (Kipp und 
Zonen, Germany) to the BNC output of the EVOMX, a continuous signal 
for TEER inside the FTPC could be recorded. In a first set of experiments 
the question in how far TEER values recorded outside and inside the 
FTPC are comparable was addressed. Therefore, TEER of three Caco-2 
cell monolayers was measured by means of handheld electrodes before 
and after insertion into the FTPC in a Transwell® plate (Figure 3-2). In the 
interim time the monolayers were mounted inside the FTPC, the 
compartments were filled with KRB pH 7.4, an apical flow rate of 1.0 
ml/min was applied and TEER was recorded (Figure 3-2).The experiments 
illustrated that after careful installation of a Transwell® a TEER similarly 
high as obtained directly before by manual measurement can be reached 
inside the FTPC. On the other hand a considerable difference between the 
TEER after two hours inside the FTPC and the manually obtained 
measurements after carful removal of the Transwell® supports from the 
FTPC was detected in all three experiments. These results suggested that 
the paracellular barrier function of the Caco-2 cells inside the FTPC might 
be kept for more than two hours and probably longer as suggested by 
TEER measurement outside the FTPC. A detailed analysis of this question 
can be found in chapter 3.6. 
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 TEER  (Ω x cm2) 
before experiment 1110 
after experiment 717 
before experiment 1010 
after experiment 478 
before experiment 892 
after experiment 345 
 
Figure 3-2 Left side: Online TEER profiles of three Caco-2 cell monolayers inside the 
FTPC. Right side: TEER of the identic monolayers measured inside a Transwell® plate 
before and after insertion into the FTPC. 
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3.5 Computer-controlled online TEER measurement 
In a further step data acquisition was assigned to a computer after A/D 
conversion of the signal, and the EVOMX was customized with a digital 
input that allowed for software controlled triggering of the TEER 
measurement. 
 
3.5.1 Adaption of the EVOMX 
Concerning the measurement equipment it was decided to stay with the 
EVOMX which is optimized for cell culture conditions and uses a four point 
probe setup for voltage measurement. The device already features an 
analogue BNC output that allows tapping voltage readouts. In order to 
provide for an option to trigger the TEER measurement electronically the 
EVOMX was customized with a relay and an associated circuit. The 
resulting parallel connection of the closing switch now allowed both 
manual and electronic triggering of TEER measurement. 
 
3.5.2 Computer-controlled measurement 
In order to allow for the computer-controlled data acquisition and triggering 
of the measurement a multifunction data acquisition device (NI-USB 6009, 
National Instruments, Munich, Germany) in combination with LabVIEW 
software (Version 8.5, National Instruments, Munich, Germany) was used 
(Figure 3-3). A custom program called virtual instrument (VI) was 
developed providing a loop with adjustable parameters like measurement 
frequency, samples to average and delay-time before measuring. A 
sampling frequency of one per minute was chosen as default setting as it 
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proofed to be sufficient to still speak of continuous TEER measurement 
and eliminated any potential questions regarding electrical polarization, 
electrode reactions or rapid material wearout. 
 
Figure 3-3  Overview of the components necessary for the computer controlled 
triggering and data acquisition of online TEER measurement inside the FTPC. 
 
3.6 Lifetime of Caco-2 cells inside the FTPC 
Aim of the study was to elucidate the time frame for which the Caco-2 cells 
keep up the paracellular barrier function. Therefore, two methods, online 
TEER and solute flux measurement were used concomitantly in order to 
monitor the status of the cell monolayer inside the FTPC. Sodium 
fluorescein was used as a hydrophilic marker compound for analysis of the 
paracellular permeability. Krebs Ringer Buffer (KRB) pH 7.4 was used as 
acceptor medium and as a basis for the donor solution containing a 
concentration of 5 µg/ml sodium fluorescein in KRB pH 7.4 (Flu-KRB). In 
the present study no solid formulations were applied. Therefore, the 
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dissolution equipment remained out of operation and the buffer solutions 
were pumped through the apical compartment of the FTPC directly. For 
this purpose a Stepdos 03® membrane dosage pump in combination with a 
pulsation absorber (KNF Neuberger, Freiburg, Germany) was used. The 
flow rate of the pump was set to 1.0 ml/min. Before each experiment a 
Caco-2 monolayer grown on a Transwell® support was inserted into the 
FTPC, both compartments were filled with preheated KRB and the apical 
pump was switched on. After 15 minutes of equilibration the experiments 
were started by the activation of computer controlled TEER measurement 
and automated sampling. A switch of donor solutions was conducted 
equally in all experiments from blank KRB to Flu-KRB in order to check the 
tightness of the cell monolayer. This switch did not show any influence on 
the course of TEER. Figure 3-4 shows the permeation of sodium 
fluorescein and reveals that the Caco-2 cell monolayers keep up their 
barrier properties inside the FTPC for nearly 3.5 hours after the start of an 
experiment. The application of the constant donor concentration of 5 µg/ml 
sodium fluorescein at the apical side led to a linear permeation behaviour 
of the compound as long as TEER remained on a high level. A mean 
apparent permeability of 0.4 ± 0.18 x 10-6 cm/s was calculated from the 
slope of the linear part of the permeated amount between 60 and 180 
minutes. This value lies within the range of reported Caco-2 permeability 
for sodium fluorescein of 0.21 – 0.623 x 10-6 cm/s [73, 74] and 
permeability did not increase until TEER dropped below 300 Ω x cm2. 
When the time of cell monolayer integrity had expired, TEER dropped to 
low values and at the same time the permeability increased strongly. 
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Figure 3-4 Time course of TEER, fluorescein transport and apparent permeability (Papp) 
as calculated from the latter. Shown are mean ± SD of n = 3 experiments. 
The finding of a value of 300 Ω x cm2 as the limit for paracellular tightness 
is in good agreement to the literature and seems to be valid also for other 
epithelial in vitro models [85]. A linear permeation pattern of sodium 
fluorescein was obtained although TEER did not remain on a constant 
level within the first three hours. The observation that certain differences in 
TEER are not reflected in the permeation profile is not an uncommon 
phenomenon for Caco-2 cells [86-88] and might partly be caused by an 
insufficient resolution of standard marker-flux measurement. Furthermore, 
it should be considered that mechanistically TEER measurement is a 
surrogate for ionic permeability and mainly based upon Na+ permeability 
[80]. So, comparing the different methods to check paracellular 
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permeability it has to be considered that TEER may measure different 
properties of the tight junctions than flux studies do. In fact, the calculation 
of pore radii from permeability data by means of the Renkin function 
revealed a nonlinear correlation between pore size and TEER in rat 
alveolar cell monolayers [89]. Nevertheless, the concept of establishing a 
minimum TEER to be maintained throughout an experiment seems to be 
an adequate tool for in process control, provided that the interrelation 
between TEER and solute permeability has been elucidated before. So, 
according to instant results a time window of three hours is available for 
combined dissolution and permeation experiments with the revised 
basolateral setup. In comparison to that, for long-term Caco-2 experiments 
in culture plates, which are usually conducted using cell culture medium 
instead of buffer solutions, experimental times and monolayer integrity of 
up to six hours have been reported [33, 90]. The reason for this difference 
is attributed to the dynamic flow through character of the setup that implies 
stronger mechanical stress on the monolayer. On the other hand three 
hours are a sufficiently long period of time to study the performance of oral 
immediate release (IR) dosage forms of BCS class III and IV compounds 
which is the main focus of the apparatus. Next to that, this precondition fits 
well to the reported human small intestinal transit time of 3 ± 1 hour [91]. 
 
3.7 Microscopic inspection of Caco-2 cells in comparison to 
TEER measurement 
In this study it was aimed to elucidate if the change in electrical properties 
also leads to changes of the cellular morphology during the course of time 
that the cells are mounted inside the FTPC. Therefore, online TEER was 
recorded and either after two hours (high TEER) or after five hours (low 
TEER) the respective Transwell® was removed. For a closer analysis the 
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cells were fixed with 4 % formalin in phosphate buffer. Afterwards the 
nuclei were stained with hematoxylin and 4 µm cross-sections of the 
polyester membranes with the Caco-2 cells on top were prepared. 
Microscopic analysis of the cross-sections was done with a Leica DMRB 
upright microscope (Leica Microsystems GmbH, Wetzlar, Germany). As 
expected, TEER was still on a high level after two hours whereas after five 
hours inside the FTPC TEER of the respective Caco-2 cell monolayer 
decreased to a low value beneath 100 Ω x cm2 (Figure 3-5). 
 
Figure 3-5  Course of TEER of two Caco-2 cell monolayers. Arrows indicate the times 
when the Transwell® supports were removed from the FTPC for microscopic analysis. 
In agreement to the course of TEER there was no morphological 
difference between the cell monolayer after two hours inside the FTPC  
(Figure 3-6b) and a monolayer that has been fixed directly after cultivation 
(Figure 3-6a). In contrast to that the cells have shrunk and the 
interconnections between adjacent cells have loosened after a period of 
five hours inside the FTPC (Figure 3-6c). Furthermore, small cavities 
between the cells and the surface of the membrane could be detected at 
that stage. 
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Figure 3-6 The figure shows cross-sections of three Caco-2 cell monolayers on top of 
polyester membranes (10 µm thickness, 0.4 µm pore size, Transwell® type 3460) at a 400 
fold magnification, nuclei were stained with hematoxylin. a: A monolayer that has been 
fixed directly after cultivation serves as a control. b: This monolayer has been fixed after it 
was inside the FTPC for two hours applying blank buffer with an apical flow rate of 1.0 
ml/min. c: This picture shows the status of a third monolayer that was inside the FTPC for 
five hours under the same conditions as described for figure 4b. 
 
3.8 Online TEER measurement as a tool for the analysis of the 
influence of excipients on cell monolayer permeability 
3.8.1 Introduction 
In order to evaluate the performance of the new setup for continuous 
TEER measurement it was decided to make use of its known dependency 
on the extracellular concentration of Ca2+. For tight monolayered epithelia 
it is known that a switch to Ca2+ free conditions causes a drop of TEER, 
resulting from an opening of the normally tight intercellular junctions. This 
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effect is even stronger if Ca2+ is actively depleted by means of a cation 
chelator, whereas after switching back to a Ca2+ containing medium TEER 
will recover again [92]. The velocity of resealing of the tight junctions was 
pointed out to be dependent on the time that the cells were kept in the 
status of Ca2+ depletion before [93]. In the vast majority of such studies the 
Ca2+ depletion was performed on both sides of the respective cell 
monolayer. Later on, a study by Noach et al. demonstrated that Caco-2 
cells react much more sensitively to the application of EDTA from the 
basolateral side than from the apical side [94]. However, in our 
experiments Ca2+ depletion was performed only from the apical side as 
this is the scenario that is of in vivo relevance. 
 
3.8.2 Buffer solutions 
EDTA solutions contained 2, 3, 6 or 8 mM EDTA next to 5 µg/ml sodium 
fluorescein and were prepared without addition of Ca2+ and Mg2+ (Flu-
EDTA). The changes in osmolality, which were caused by the addition of 
EDTA and the omission of the divalent ions, were compensated to the 
calculative value of KRB using NaCl. Isoosmolality of all solutions of 308 ± 
4 mosmol/kg was controlled via freezing point depression (Semi-micro 
Osmometer, Knauer GmbH, Berlin, Germany). All solutions were adjusted 
to pH 7.4 in order to exclude influences on solute transport or electric 
measurement caused by a pH gradient between the apical and the 
basolateral compartment. 
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3.8.3 Experimental procedure 
In order to analyze the modulation of cell monolayer tightness, the donor 
medium was switched to a Flu-EDTA solution for a certain period of time to 
illustrate some permeation enhancing effect on the monolayer and back 
again to Flu-KRB. Switching between the different donor solutions was 
feasible without interruption of the apical flow and without aspiration of any 
air bubbles due to the discontinuous suction of the membrane pump. In 
preliminary tests a time frame of 45 minutes for application of Flu-EDTA 
solutions was found to be suitable for the experiments. Starting with the 
highest concentration of 8 mM a step by step reduction of the EDTA 
concentration was conducted in the experiments shown in Figure 3-7. 
 
3.8.4 Results 
The application of high EDTA concentrations of 8 and 6 mM led to a 
pronounced drop of TEER and after switching back to Ca2+-containing Flu-
KRB solution no stabilisation was reached. In agreement with the course 
of TEER the permeability of sodium fluorescein increased after application 
of the Flu-EDTA solutions and no reduction or slowing down of this 
process after Ca2+ restoration was observed. In coincidence with the 
ongoing drop of TEER the cumulative amount of sodium fluorescein 
showed a parabolic profile, corroborating a continuously increasing 
permeability of the monolayer. Reduction of the EDTA concentration to 3 
and 2 mM led to a different picture. After the EDTA induced drop, TEER 
recovered as soon as Ca2+ was available in the apical medium again. 
Within the period of TEER recovery the cumulative amount of permeated 
sodium fluorescein increased linearly and permeability persisted at an 
almost constant level. Only when the expected time span of cell monolayer 
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integrity ended after about 3.5 hours inside the FTPC epithelial 
permeability increased again. 
 
Figure 3-7 Application of 8, 6, 3 and 2 mM EDTA containing buffer for a time interval of 
45 minutes and subsequent return to KRB. All solutions applied later than 15 minutes 
after the start of an experiment contained 5 µg/ml of sodium fluorescein (Flu-KRB; Flu-
EDTA). TEER values were normalized to the maximum value of the respective 
experiment in order to allow for a better comparability of the EDTA effect. The figure 
shows single data for each EDTA concentration. 
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3.8.5 Recovery of TEER after repeated Ca2+ switching 
Afterwards, a repeated switching between Flu-EDTA and Flu-KRB solution 
was evaluated. As can be seen in Figure 3-8, switching between 8 mM 
Flu-EDTA and Flu-KRB for four times with an exposure to the Ca2+ 
chelator for only ten minutes each time led to a stepwise decrease of 
TEER and was followed by a decreasing capability of the cells to recover 
again. Despite that, the cumulative amount of permeation showed a 
parabolic shape and the flux over the monolayer increased steadily with a 
tendency to increase above average after three hours, as already seen in 
the previous experiments. 
 
Figure 3-8 Change in cell monolayer leakiness following four 10 minutes applications 
(hatched areas) of 8 mM EDTA assessed during the course of the same experiment. 
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3.8.6 Discussion 
EDTA induced Ca2+ depletion from the apical compartment led to a 
pronounced drop of TEER. Synopsis of the experiments with identical 
procedure and an application of 8 to 2 mM EDTA for 45 minutes revealed 
a concentration dependent decrease of TEER within the time of exposure 
to the chelating agent. Comparison of the respective permeability that was 
reached after 200 minutes, the time that the cell monolayer integrity was 
shown to be limited to, also reflected the rank order of EDTA 
concentrations (Figure 3-7). Next to that, a dose dependency was found 
for the recovery of TEER after switching back to Flu-KRB solution. 
Whereas after application of higher EDTA concentrations (8 and 6 mM) for 
45 minutes, the decrease of TEER was irreversible, the exposure to lower 
EDTA concentrations (3 and 2 mM) was followed by a recovery of the 
TEER (Figure 3-7). A closer look upon sodium fluorescein permeation 
throughout the periods of TEER recovery revealed a linear increase of the 
permeated amount and a constant permeability on a higher level in 
comparison to an unaffected cell monolayer. It was concluded that 
recovery of TEER in this case did not lead to a complete resealing but to a 
conservation of the current permeability of the Caco-2 monolayer for 
sodium fluorescein. In this context a study by Watson et al. who have 
introduced a novel tool that allows detection of graded changes in 
paracellular permeability provided helpful mechanistic insight [95]. By 
means of simultaneous permeability screening of a series of polyethylene 
glycol oligomers (PEG-profiling) the authors pointed out that upon Ca2+ 
chelation the cell monolayer lost its ability for size discrimination. 
Functional modelling suggested an increase in pore size as the underlying 
mechanism. The evaluation of PEG-profiling with different EDTA 
concentrations conducted by the same authors did not result in a clear 
gradation for the effect of Ca2+ depletion. This might be caused by the fact 
that the Ca2+ chelator was also added to the highly sensitive basolateral 
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side of the cell monolayer. Higher EDTA concentrations (8 and 6 mM) did 
not lead to a recovery but showed a continuously decreasing TEER. In 
agreement to that finding, the permeated amount of sodium fluorescein 
showed a nonlinear growth and the permeability was increasing steadily. 
So it was concluded that the process of pore size increase initiated by 
EDTA in these cases could not be stopped by means of Ca2+ reconstitution 
anymore. 
In comparison to flux studies TEER measurement is the more sensitive 
method with a high temporal resolution [96]. However, this advantage 
reveals its full value only in case of continuous recording which could be 
pointed out by repeated switches to 8 mM Flu-EDTA and back to Ca2+ 
containing buffer (Figure 3-8). In contrast to the instantaneous and 
sensitive response of TEER upon the repeated short term EDTA 
application the permeability of sodium fluorescein followed with a certain 
delay and did not show a gradation. It was concluded that the time periods 
of 30 minutes in between the single EDTA bolus applications were too 
short for detection of an equilibration of the flux. 
In consequence the different methods to characterize paracellular 
permeability of an epithelial cell monolayer provide complementary 
information and have to be interpreted cautiously. In order to get a 
complete picture of the state of paracellular permeability, combinations of 
TEER and diffusion measurement would be required [75]. Furthermore, it 
has to be considered that membrane permeation even of hydrophilic drugs 
may not solely be based upon one single paracellular mechanism. Sodium 
fluorescein, which longtime has been regarded as the standard marker 
dye for paracellular transport, seems to be transported actively in case of 
application of a pH gradient between the apical and the basolateral 
compartment and was stated to be substrate of a proton coupled 
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monocarboxylic anion transporter [97, 98]. Therefore, in this study all 
experiments have been carried out under iso-pH conditions of pH 7.4 on 
both sides of the cell monolayer which is supposed to limit epithelial 
transport to the paracellular route. The TEER of a Caco-2 cell monolayer 
grown on a permeable support is highly sensitive to surrounding conditions 
like buffer changes and temperature drops. Thus, equilibration periods 
under controlled conditions for at least 15 minutes after each manipulation 
are required in order to obtain reliable TEER values [75]. Here our setup 
offers advantages by its design as a flow through system providing a 
seamless transition of the donor composition inside the apical 
compartment. Due to the relatively high heat capacity of 
polyetheretherketone (PEEK) used to manufacture the FTPC and 
submersion into a preheated water bath, an equilibration is only necessary 
at the start of an experiment. Finally, the availability of only two single 
TEER values, one measured before and one after an experiment in 
absence of constant external conditions, are to be regarded as insufficient. 
Continuous TEER measurement inside the FTPC is much more reliable 
and less error prone. 
 
3.8.7 Conclusions 
Cell monolayer integrity and, regarded with a closer focus, the actual 
status of the paracellular permeability are critical parameters that should 
be controlled during a transport experiment across Caco-2 cells. This 
applies especially in case of intentional manipulation of the cell monolayer 
permeability as purposed with the apparatus. By means of continuous 
TEER measurement a sensitive tool for online monitoring of the barrier 
status of Caco-2 cell monolayers has been implemented into the 
apparatus for combined measurement of dissolution and permeation. The 
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instantaneous availability of the respective TEER profile to each 
experiment provides an adequate in-line control and points out the validity 
of the experimental data. Next to that, the informative value of the online 
and on-site TEER measurement is much higher in comparison to the prior 
situation, when TEER could only be measured outside the FTPC, before 
and after an experiment. However, it has to be considered that TEER 
measurement cannot provide a complete picture of the paracellular 
permeability. Therefore, a careful interpretation of the data is essential to 
obtain a deeper insight into the changes at the cell monolayer. The novel 
feature will allow investigating advanced formulation approaches for oral 
drug delivery and it helps understanding the interplay of drugs and 
excipients with the intestinal barrier. Finally it aims for the establishment of 
rationales for the incorporation of permeation enhancers or combinations 
of excipients with additional physicochemical or biological targets such as 
efflux pumps and gut wall associated metabolic enzymes into solid oral 
drug formulations. 
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4 Proof of concept using the BCS class IV 
compound furosemide 
4.1 Permeation of furosemide in the revised apparatus 
After successful adaption of the apparatus for the analysis of low perme-
able compounds, installation of online TEER measurement and the analy-
sis of excipient effects on cell monolayer integrity, it was decided to reas-
sess the BCS class IV compound furosemide with the revised equipment 
under the same conditions as described in chapter 2.2.3. In this study it 
was of particular interest to clarify if the compound now featured a reason-
able permeation. Therefore, Lasix® 40 mg IR tablets were analyzed in two 
sets of experiments applying either a single tablet (Figure 4-1) or two of 
the tablets at one time inside the flow through dissolution cell (Figure 4-2). 
 
Figure 4-1 Analysis of single Lasix® 40 mg IR tablets. Closed circles (●) represent the 
furosemide concentration measured at sampling port D, open circles (○) the 
concentrations at port A and triangles down (▼) point out the amount of drug that 
permeated into the basolateral compartment (n = 3). 
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Figure 4-2 Analysis of 2 Lasix® 40 mg IR tablets inside the dissolution cell. Closed circles 
(●) represent the furosemide concentration measured at sampling port D, open circles (○) 
the concentrations at port A and triangles down (▼) point out the amount of drug that 
permeated into the basolateral compartment (n = 3). 
Next to the drug concentrations the course of TEER was recorded pointing 
out that the barrier function of the cell monolayers was maintained 
throughout the experiments (Figure 4-3, Figure 4-4). 
 
Figure 4-3: Course of TEER inside the FTPC during the experiments analyzing single 
Lasix® tablets. 
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Figure 4-4: Course of TEER inside the FTPC during the experiments analyzing 2 Lasix® 
tablets in each experiment. 
Comparing the AUCs of the curves for one and two tablets an 
approximately twofold increase was found at the apical and the basolateral 
port (Table 4-1). 
 AUC 1 tablet AUC 2 tablets Ratio 
D 9314 15549 1.67 
A 7292 14089 1.93 
B 40 86 2.15 
Table 4-1 Comparison of the AUCs for the dissolution and permeation experiments using 
either a single or two Lasix® tablets at the same time. 
The weaker dose linearity calculated for port D might be attributed to the 
rapid release of the compound from the Lasix® formulation leading to a 
pronounced peak in the dissolution profile which was difficult to describe 
with the available number of sampling points. With 0.58 ± 0.32 µg for one 
tablet and 1.27 ± 0.57 µg for two tablets, the absolute amounts of drug that 
permeated across the cell monolayer were very low. Relative to the 
amount of drug that cumulatively appeared at the apical port a percentage 
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of 0.0080 % for the single tablet and 0.0090 % for two tablets was 
calculated. In comparison to approximately 0.35% of drug permeation for 
propranolol IR tablets (chapter 1.4.1) this revealed a 44 to 39 times lower 
extent of permeation of furosemide. In conclusion this study demonstrated 
that next to the analysis of fluorescent dyes the revised apparatus allows 
the analysis of formulations containing low permeable compounds which is 
a prerequisite for the future evaluation of e.g. formulation factors, 
excipients and dissolution media on the performance of BCS class III and 
IV compounds. 
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5 Summary and outlook 
In the present work several achievements have been made that advance 
the applicability of the apparatus for combined measurement of dissolution 
and permeation of solid oral dosage forms. In a first step, the challenge to 
allow the analysis of low permeable compounds has been addressed. In 
this process the basolateral compartment has been revised which 
provided for an abolishment of the multiple subdivisions, the minimization 
of the acceptor volume and a simplification of the handling. Next to that, 
an intrinsic carry-over effect at the valve of the automation module has 
been identified as a major cause for the unexpectedly high and 
inconsistent concentrations of furosemide measured at the basolateral 
sampling port. This issue could be circumvented by installation of a 
second valve for basolateral sampling separating the routes for high 
concentration assessment at port D and A from the much lower 
concentrations to be detected at port B. The proper function of the revised 
apparatus was pointed out using sodium fluorescein and rhodamine 123 
as marker compounds for low permeability. Next to the adaptation of the 
apparatus for the analysis for low permeable compounds it was aimed to 
provide for the option to monitor cell monolayer integrity inside the FTPC. 
This was realized by implementation of online TEER measurement which 
was pointed out to be a valuable method supporting and completing the 
results from marker flux measurement. Applying both methods, the viability 
of the Caco-2 cell monolayers inside the revised apparatus was 
determined to roughly 3.5 hours. In the next step it was evaluated if the 
novel feature of online TEER measurement could also be used as a tool to 
analyze the influence of excipients on cell monolayers. In this context the 
known relationship between Ca2+ availability and functional tight junctions 
was utilized applying EDTA solution in the apical compartment for certain 
periods of time. Simultaneously the flux of the paracellular marker sodium 
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fluorescein was measured and online TEER was recorded revealing 
interesting relations and advantages of the complementary methods and 
encouraging testing online TEER measurement in an approach that uses 
excipients incorporated into complete solid oral dosage forms as a next 
step. In this context two approaches might be of interest. At first a 
compound that is substrate of epithelial efflux transport like furosemide or 
digoxin could be coadministered with an efflux inhibitor like TPGS at 
different doses. Digoxin might be of interest, as for this compound a 
marketed soft gelatin capsule is available in the US (Lanoxicaps™). 
Absorption of digoxin from this formulation is reported to be 90 - 100%, 
whereas standard digoxin tablets provide a bioavailability of 60 to 80% 
(http://www.drugs.com/pro/lanoxicaps.html). In a second step it could also 
be interesting to evaluate the most promising compounds proposed by 
Whitehead et al. [30, 31]. Although the mechanism of permeation 
enhancement for some of the compounds that have been elucidated in 
those studies is unknown, the enhancers and strategies to circumvent 
toxicity proposed by the authors might be interesting to be evaluated using 
the apparatus for combined measurement of dissolution and permeation. 
A further point of interest is the implementation of cell culture compatible 
biorelevant dissolution media aiming for the estimation of a potential food 
effect. In contrast to the standard procedure that uses the dissolution 
profile in USP apparatus 2 as a criterion, the apparatus allows to also 
consider the successive and maybe even more significant criterion of 
permeation next to analysis of the dissolution profile. 
So, the field of combined dissolution and permeation testing definitively 
offers further interesting opportunities for research. Practical relevance of 
such efforts will be provided by the opportunity to analyze complete oral 
dosage forms. 
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6 Annexes 
6.1 List of abbreviations 
ADME absorption, distribution, metabolisation and elimination 
API  active pharmaceutical ingredient 
AUC  area under the curve 
BCS  biopharmaceutical classification system 
BE  bioequivalence 
BNC  bayonet Neill-Concelman 
conc. concentration 
CYP  cytochrome P 
EDTA Ethylenediaminetetraacetic acid disodium salt 
e.g.  exempli gratia 
et al.  et alii 
ER  extended release 
EVOM epithelial volt ohm meter 
FDA  Food and Drug Administration 
Flu-EDTA Krebs Ringer buffer containing sodium fluorescein and EDTA 
Flu-KRB Krebs Ringer buffer containing sodium fluorescein 
FTPC flow through permeation cell 
HPLC high pressure liquid chromatography 
IR  immediate release 
IVIVC in vitro-/ in vivo correlation 
KRB  Krebs Ringer buffer 
LOD  limit of detection 
LOQ  limit of quantification 
no.  number 
PAMPA parallel artificial membrane permeability assay 
Papp  apparent permeability coefficient 
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PEEK polyetheretherketone 
PEG  polyethylene glycol 
P-gp  P-glycoprotein 
PMT-FL photomultiplier tube for fluorescence detection 
SIA  sequential injection analysis 
SD  standard deviation 
TEER transepithelial electrical resistance 
TPGS tocopheryl polyethylene glycol succinat 
USP  United States Pharmacopoeia 
UV  ultra violet light 
VIS  visible light 
WHO World Health Organization 
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6.2 Allocation of the ports at the SIA valves 
6.2.1 8-port valve 
Port number Port appelation 
1 WASTE 
2 UV VIS 
3 PMT-FL 
4 DISSOLUTION 
5 APICAL 
6 BASOLATERAL 
7 KRB SUPPLY 
8 AUTOSAMPLER 
 
6.2.2 6-port valve 
Port number Port appelation 
1 Müll 
2 Buffer 
3 Akzeptorkompartiment 
4 Probensammler 
5 Abfall 
6 6 
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6.3 Programming codes for SIA automation 
6.3.1 SIA programs for furosemide 
Main routine furosemide 
Hardware Settings Wavelength 1 (nm) 275 
Hardware Settings Wavelength 2 (nm) 274 
Hardware Settings Wavelength 3 (nm) 344 
Hardware Settings Wavelength 4 (nm) 360 
 
autosampler Command: Set port 5 
Spectrometer Reference Scan 
Delay (sec) 145 
 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\dissolution_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\dissolution_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\apical_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\dissolution_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid \apical_flowrate 10.fia 
 
Variable Define New sampos 
 
sampos = 1 
 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\basolateral_new_compartment 
_new_valve.fia 
 
sampos += 1 
 
Loop Start (#) 40 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\dissolution_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\apical_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\dissolution_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\apical_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\dissolution_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\apical_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\dissolution_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\apical_flowrate 10.fia 
Insert File C:\Programme\WINFIA 5.0\Marco\Furosemid\basolateral_new_compartment 
_new_valve.fia 
 
sampos += 1 
 
Loop end 
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Subroutine: dissolution_flowrate 10.fia 
Syringe Pump Valve In 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 750 
Multiposition Valve dissolution 
Syringe Pump Delay Until Done 
Syringe Pump Valve Out 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done  
Multiposition Valve Waste 
Syringe Pump Flowrate (microliter/sec) 100 
Syringe Pump Dispense (microliter) 300 
Syringe Pump Delay Until Done  
Multiposition Valve dissolution  
Syringe Pump Flowrate (microliter/sec) 10 
Syringe Pump Aspirate (microliter) 50 
Syringe Pump Delay Until Done 
Delay (sec) 1 
Multiposition Valve UV- detector  
Syringe Pump Flowrate (microliter/sec) 1 
 
Analyte New Sample  
Analyte Name Dis 
Spectrometer Absorbance Scanning 
Delay (sec) 1 
Syringe Pump Dispense (microliter) 300 
Syringe Pump Delay Until Done 
Spectrometer Stop Scanning 
 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Empty 
Syringe Pump Delay Until Done 
 
 
Subroutine apical_flowrate 10.fia 
Syringe Pump Valve In 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 800 
Multiposition Valve apical 
Syringe Pump Delay Until Done 
Syringe Pump Valve Out 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Aspirate (microliter) 150 
Syringe Pump Delay Until Done  
Multiposition Valve Waste 
Syringe Pump Flowrate (microliter/sec) 100 
Syringe Pump Dispense (microliter) 400 
Syringe Pump Delay Until Done  
Multiposition Valve apical 
Syringe Pump Flowrate (microliter/sec) 10 
Syringe Pump Aspirate (microliter) 50 
82 
Annexes 
Syringe Pump Delay Until Done  
Delay (sec) 1 
Multiposition Valve UV- detector 
Syringe Pump Flowrate (microliter/sec) 10 
 
Analyte New Sample 
Analyte Name Api 
Spectrometer Absorbance Scanning 
 
Delay (sec) 1 
Syringe Pump Dispense (microliter) 300 
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Empty 
Syringe Pump Delay Until Done 
 
 
Subroutine: basolateral_new_compartment_new_valve.fia 
Basolateral Pump Valve In 
Basolateral Pump Flowrate (microliter/sec) 50 
Basolateral Pump Aspirate (microliter) 325 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve Out 
Basolateral Valve Akzeptorkompartiment  
Basolateral Pump Flowrate (microliter/sec) 10 
Basolateral Pump Aspirate (microliter) 100 
Basolateral Pump Delay Until Done 
Basolateral Valve Abfall 
Basolateral Pump Dispense (microliter) 125 
Basolateral Pump Delay Until Done 
Basolateral Valve 6 
autosampler Wash 
Basolateral Pump Flowrate (microliter/sec) 10 
Basolateral Pump Aspirate (microliter) 25 
Basolateral Pump Delay Until Done  
Basolateral Valve Akzeptorkompartiment 
Basolateral Pump Aspirate (microliter) 100 
Basolateral Pump Delay Until Done 
Basolateral Valve 6 
Basolateral Pump Aspirate (microliter) 25 
Basolateral Pump Delay Until Done  
autosampler standard rack (sample #) 10 
Delay (sec) 3 
Basolateral Valve Probensammler 
Basolateral Pump Flowrate (microliter/sec) 20 
Basolateral Pump Dispense (microliter) 220 
Basolateral Pump Delay Until Done 
autosampler RACK 2 (sample #) = sampos 
Delay (sec) 3 
Basolateral Pump Dispense (microliter) 110 
Basolateral Pump Delay Until Done 
autosampler standard rack (sample #) 10 
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Delay (sec) 3 
Basolateral Pump Valve In 
Basolateral Pump Flowrate (microliter/sec) 50 
Basolateral Pump Fill 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve Out 
Basolateral Pump Empty 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve In 
Basolateral Pump Fill 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve Out 
Basolateral Pump Empty 
Basolateral Pump Delay Until Done 
autosampler Wash 
 
6.3.2 SIA programs for fluorescein and rhodamine 
Spectrometer (PMT-FL) settings: 
Integration time [ms]: 50 
Sampling rate [Hz]: 4 
 
Main routine fluorescein/ rhodamine 
 
Variable Define New sampos 
sampos = 1 
 
Insert File C:\Programme\WINFIA 5.0\Marco\basolaterale Pumpe&Ventil\subroutinen\ 
Abfüllung basolateral in 96 well plate.fia 
 
sampos += 1 
 
Insert File C:\Programme\WINFIA 5.0\Marco\basolaterale Pumpe&Ventil\subroutinen\ 
Probenzug apical V50_Flow25_50ms_4Hz- neuer Probenzug_1500.fia 
Delay (sec) 640 
 
Insert File C:\Programme\WINFIA 5.0\Marco\basolaterale Pumpe&Ventil\subroutinen\ 
Abfüllung basolateral in 96 well plate.fia 
 
sampos += 1 
 
Insert File C:\Programme\WINFIA 5.0\Marco\basolaterale Pumpe&Ventil\subroutinen\ 
Probenzug apical V50_Flow25_50ms_4Hz- neuer Probenzug_1500.fia 
Delay (sec) 340 
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Insert File C:\Programme\WINFIA 5.0\Marco\basolaterale Pumpe&Ventil\subroutinen\ 
Probenzug apical V50_Flow25_50ms_4Hz- neuer Probenzug_1500.fia 
Delay (sec) 200 
 
Loop Start (#) 60 
 
Insert File C:\Programme\WINFIA 5.0\Marco\basolaterale Pumpe&Ventil\subroutinen\ 
Abfüllung basolateral in 96 well plate.fia 
 
Insert File C:\Programme\WINFIA 5.0\Marco\basolaterale Pumpe&Ventil\subroutinen\ 
Probenzug apical V50_Flow25_50ms_4Hz- neuer Probenzug_1500.fia 
 
sampos += 1 
 
Delay (sec) 1540 
 
Loop End 
 
 
Subroutine: Probenzug apical V50_Flow25_50ms_4Hz- neuer 
Probenzug_1500.fia 
Syringe Pump Valve In 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 1500 
Syringe Pump Delay Until Done  
Syringe Pump Valve Out  
Multiposition Valve apical  
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done  
Multiposition Valve waste  
Syringe Pump Flowrate (microliter/sec) 100 
Syringe Pump Dispense (microliter) 200 
Syringe Pump Delay Until Done 
Multiposition Valve apical 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 50 
Syringe Pump Delay Until Done 
Multiposition Valve PMT-FL 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Empty 
 
Analyte New Sample 
Analyte Name apical 
PMT Start Scans 
Syringe Pump Delay Until Done 
PMT Stop Scans 
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Subroutine: Abfüllung basolateral in 96 well plate 
Basolateral Pump Valve In 
Basolateral Pump Flowrate (microliter/sec) 50 
Basolateral Pump Aspirate (microliter) 325 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve Out 
Basolateral Valve Akzeptorkompartiment  
Basolateral Pump Flowrate (microliter/sec) 10 
Basolateral Pump Aspirate (microliter) 100 
Basolateral Pump Delay Until Done  
Basolateral Valve Abfall  
Basolateral Pump Dispense (microliter) 125 
Basolateral Pump Delay Until Done 
Basolateral Valve 6 
autosampler Wash 
Basolateral Pump Flowrate (microliter/sec) 10 
Basolateral Pump Aspirate (microliter) 25 
Basolateral Pump Delay Until Done  
Basolateral Valve Akzeptorkompartiment  
Basolateral Pump Aspirate (microliter) 100 
Basolateral Pump Delay Until Done 
Basolateral Valve 6 
Basolateral Pump Aspirate (microliter) 25 
Basolateral Pump Delay Until Done 
autosampler standard rack (sample #) 10 
Delay (sec) 3 
Basolateral Valve Probensammler 
Basolateral Pump Flowrate (microliter/sec) 20 
Basolateral Pump Dispense (microliter) 220 
Basolateral Pump Delay Until Done 
autosampler RACK 4 (sample #) = sampos 
Delay (sec) 3 
Basolateral Pump Dispense (microliter) 110 
Basolateral Pump Delay Until Done 
autosampler standard rack (sample #) 10 
Delay (sec) 3 
Basolateral Pump Valve In 
Basolateral Pump Flowrate (microliter/sec) 50 
Basolateral Pump Fill 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve Out 
Basolateral Pump Empty 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve In 
Basolateral Pump Fill 
Basolateral Pump Delay Until Done 
Basolateral Pump Valve Out 
Basolateral Pump Empty 
Basolateral Pump Delay Until Done 
autosampler Wash 
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6.3.3 Test routine for the multiposition-valve 
Spectrometer (PMT-FL) settings: 
Integration time [ms]: 80 
Sampling rate [Hz]: 4 
 
Main routine 
Loop Start (#) 60 
 
Insert File C:\Programme\WINFIA 5.0\Marco\Propranolol\probenzug 25\Probenzug 
dissolution 25- neuer Propenzug.fia 
Insert File C:\Programme\WINFIA 5.0\ Marco\Propranolol\probenzug 25\Probenzug 
apical 25- neuer Probenzug.fia 
 
Loop End 
 
Subroutine: Probenzug dissolution 25- neuer Propenzug.fia 
Syringe Pump Valve In 
Syringe Pump Flowrate (microliter/sec) 250 
Syringe Pump Aspirate (microliter) 1000 
Syringe Pump Delay Until Done  
 
Syringe Pump Valve Out 
Multiposition Valve dissolution 
Syringe Pump Flowrate (microliter/sec) 100 
Syringe Pump Aspirate (microliter) 50 
Syringe Pump Delay Until Done  
 
Multiposition Valve waste  
Syringe Pump Flowrate (microliter/sec) 200 
Syringe Pump Dispense (microliter) 100 
Syringe Pump Delay Until Done  
 
Multiposition Valve dissolution 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Aspirate (microliter) 25 
Syringe Pump Delay Until Done  
 
Multiposition Valve PMT-FL 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Empty  
 
Analyte New Sample  
Analyte Name dissolution 
PMT Start Scans  
Syringe Pump Delay Until Done  
PMT Stop Scans 
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Subroutine: Probenzug apical 25- neuer Probenzug.fia 
Syringe Pump Valve In 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 1000 
Syringe Pump Delay Until Done  
Syringe Pump Valve Out  
Multiposition Valve apical  
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done 
Multiposition Valve waste  
Syringe Pump Flowrate (microliter/sec) 200 
Syringe Pump Dispense (microliter) 200 
Syringe Pump Delay Until Done  
Multiposition Valve apical  
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 25 
Syringe Pump Delay Until Done  
Multiposition Valve PMT-FL 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Empty 
 
Analyte New Sample  
Analyte Name apical 
PMT Start Scans  
Syringe Pump Delay Until Done 
PMT Stop Scans 
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6.4 Autosampler configuration 
Configuration of the autosampler rack for sampling into HPLC vials: 
 
Name of rack: RACK 2 
Number of rows: 3 
Number of columns: 13 
X Position of Sample #1 (mm): 75 
Y Position of Sample #1 (mm): 19 
Delta X Position of Samples in rack (mm): 15 
Delta Y Position of Samples in rack (mm): 18 
Up Position (mm): 50 
Down Position (mm): 117 
 
Configuration of the autosampler rack for sampling into 96 well plates: 
 
Name of rack: RACK 4 
Number of rows: 12 
Number of columns: 8 
X Position of Sample #1 (mm): 76 
Y Position of Sample #1 (mm): 23 
Delta X Position of Samples in rack (mm): 9 
Delta Y Position of Samples in rack (mm): 9 
Up Position (mm): 50 
Down Position (mm): 142 
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6.5 PEEK adapter for electrode plugs 
 
Figure 6-1 Detail drawing of the PEEK adapter for installation of wiring and plugs of 
electrodes for online TEER measurement inside the FTPC. 
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7 Curriculum vitae 
personal details  
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date of birth 
place of birth 
Marco Mündörfer 
15.09.1979 
Karlsruhe, Germany 
education  
1986 – 1990 
1990 – 1999 
Grundschule Aue 
Markgrafen-Gymnasium Durlach 
public service  
1999 – 2000 Arbeiterwohlfahrt Karlsruhe 
university studies  
October 2000 –  
March 2005 
Albert-Ludwigs-Universität, Freiburg, study of 
Pharmacy 
internships  
May 2005 –  
October 2005 
Department of Biopharma-Operations, 
Manufacturing Science, Boehringer-Ingelheim 
Pharma GmbH, Biberach / Riss 
November 2005 –  
April 2006 
Elisabeth-Apotheke, Dresden 
professional qualification 
June 2006 Registration as a pharmacist 
work experience  
July 2006 –  
October 2006 
Ludwig-Maximilians-Universität, Munich, scientific 
employee 
PhD thesis  
January 2007 –  
April 2010 
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